



**Vaccines and Global Health: The Week in Review**  
**04 January 2025 :: Issue 780**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

***Contents [click to move among sections]***

*:: [Milestones, Perspectives](#)*

*:: [WHO](#)*

*:: [Organization Announcements](#)*

*:: [Journal Watch](#)*

*:: [Pre-Print Servers](#)*

*:: [Think Tanks](#)*

*:: [Public Consultations/Call for Inputs/Call for Papers](#)*

***Editor's Note:***

***Vaccines and Global Health: The Week in Review resumes publication with this 04 January 2025 edition following an end-of-year, holiday break.***

## *Milestones, Perspectives*

.....  
.....

### **Yemen**



#### **Tedros Adhanom Ghebreyesus**

@DrTedros

5:14 AM · Dec 28, 2024

Thank you to all my friends, colleagues, and everyone who has wished me well during the ordeal in the past few days.

I'm especially grateful to the colleagues and airport staff, who were selfless as they tried to protect me.

We faced a very dangerous attack, but my @UN colleagues and I are now safe. We successfully evacuated our wounded colleague to Amman, and he is stable.

My heart goes out to our colleagues on the front lines and the civilians who face such danger every day. I am on my way back home to Geneva.

.....  
.....

### **WHO Funding**

*We understand such U.S. awards are subject to available funding, and Executive Branch or Congressional action.*

#### **Notice of Award of a Sole Source Cooperative Agreement To Fund World Health Organization (WHO)**

A Notice by the U.S. Centers for Disease Control and Prevention on 12/27/2024

##### ***SUMMARY:***

The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces **the award of approximately \$20,000,000, with an expected total funding of approximately \$100,000,000 over a 5-year period, to World Health Organization (WHO)**. The award aims to support CDC and the WHO's continued collaboration to address global capacity to identify, respond, and prevent infectious diseases.

##### ***DATES:***

The period for this award will be September 30, 2025 through September 29, 2030.

##### ***SUPPLEMENTARY INFORMATION:***

**The sole source award will ensure coordination between CDC and the WHO and contribute to the response to disease outbreaks and other health emergencies**, both through capacity building and direct response to active emergencies.

**WHO is the only entity that can carry out this work, as it has a robust global infrastructure** that gives it direct access to national ministries of health and other critical health institutions through its headquarters in Geneva and six regional offices. **WHO will enhance global and regional preparedness, surveillance, and laboratory capacity to test for and respond to epidemic and pandemic-prone diseases.**

*Summary of the Award*

*Recipient:* World Health Organization (WHO).

*Purpose of the Award:* The purpose of this award is to support implementation of infrastructure and collaborations between CDC and the WHO to **build capacities needed to rapidly detect and contain disease outbreaks at the source and prevent their international spread**. NOFO activities will ensure coordination between CDC and the WHO and contribute to the response to disease outbreaks and other health emergencies, both through capacity building and direct response to active emergencies...

*Period of Performance:* September 30, 2025 through September 29, 2030.

.....  
.....

## **Pandemic Fund**

### **The Pandemic Fund Announces Third Round of Funding, Marking Another Milestone in Pandemic Preparedness**

Washington, D.C., December 19, 2024 — The Pandemic Fund's Governing Board approved a **grant envelope of \$500 million for its third round of funding to help low- and middle-income countries** scale up efforts to build health systems capacity in disease surveillance, diagnostics and laboratory systems, and health workforce—the three critical building blocks to prevent and respond to future pandemics.

**Interested countries, Regional Entities, and Implementing Entities will be able to submit proposals through an online portal starting in March 2025.** The third Call will be launched in two phases—the first phase will be open to single and multi-country proposals in March 2025; the second phase will open in June 2025 to Regional Entity proposals. In developing and implementing proposals, as laid out in the medium-term Strategic Plan, particular attention should be paid to four underlying themes—One Health, community and civil society engagement, and gender and health equity—as well as investments in strengthening two cross-cutting enablers—National Public Health Institutes (or other public institutions) and regional or global networks, organizations, or hubs...

Against a backdrop of tremendous demand for funding that outstrips available resources, **the Pandemic Fund embarked on a near-term fundraising effort in July 2024. Five months into the resource mobilization campaign, with up to US\$1 billion in new pledges from governments**, the Fund is more than halfway toward meeting its short-term fundraising goal of US\$2 billion and has secured commitments of support from new philanthropies and private sector organizations. The campaign will continue through Spring 2025.

### ***About the Pandemic Fund***

**Launched in November 2022 by leaders of the Group of 20 nations and hosted by the World Bank Group, the Pandemic Fund is the first multilateral financing mechanism of its kind** dedicated to helping low- and middle-income countries be better prepared for emerging pandemic threats. Grants from the Pandemic Fund catalyze co-financing from governments and support from an array of accredited Implementing Entities.

**The Pandemic Fund's Governing Board includes equal representation of sovereign contributors and co-investor countries, as well as representatives from foundations/non-sovereign contributors and civil society organizations.** In its first year of operation, the Pandemic Fund raised \$2 billion in seed capital from 27 sovereign and philanthropic contributors.

**Since its establishment in 2022, the Pandemic Fund has awarded, through its two funding rounds, grants totaling US\$885 million, mobilizing an additional US\$6 billion in resources** for pandemic prevention, preparedness, and response (PPPR) investments for 75 countries across six geographic regions. A total of 47 projects have received funding to date through the two rounds.




## COVID

### [Milestone: COVID-19 five years ago](#)

30 December 2024 *WHO Statement*

Five years ago on 31 December 2019, WHO's Country Office in China picked up a media statement by the Wuhan Municipal Health Commission from their website on cases of 'viral pneumonia' in Wuhan, China. In the weeks, months and years that unfolded after that, COVID-19 came to shape our lives and our world.



<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline>

At WHO, we went to work immediately as the new year dawned. WHO employees activated emergency systems on 1 January 2020, and informed the world on 4 January. By 9-12 January, WHO had published its first set of comprehensive guidance for countries, and on 13 January, we brought together partners to publish the blueprint of the first SARS-CoV-2 laboratory test.

All along, we convened experts and ministries of health from around the world, gathered and analysed data, and shared what was reported, what we learned and what it meant for people. Read about WHO's actions in this [interactive timeline](#).

As we mark this milestone, let's take a moment to honour the lives changed and lost, recognize those who are suffering from COVID-19 and long COVID, express gratitude to the health workers who sacrificed so much to care for us, and commit to learning from COVID-19 to build a healthier tomorrow.

We continue to call on China to share data and access so we can understand the origins of COVID-19. This is a moral and scientific imperative. Without transparency, sharing, and cooperation among countries, the world cannot adequately prevent and prepare for future epidemics and pandemics.

As we pose the question, "Is the world better prepared for the next pandemic than we were for COVID-19?" see WHO Director-General Dr Tedros Adhanom Ghebreyesus's response at a recent press conference: <https://who.canto.global/b/SHEJL>

.....  
.....

## Children in Conflict

### 'Not the new normal' – 2024 'one of the worst years in UNICEF's history' for children in conflict

NEW YORK, 28 December 2024 – The impact of armed conflicts on children around the world reached devastating and likely record levels in 2024, according to a review by UNICEF of the latest available data and prevailing global trends.

More children than ever are estimated to be either living in conflict zones or forcibly displaced due to conflict and violence. **A record number of children affected by conflict are having their rights violated, including being killed and injured<sup>[1]</sup>, out of school, missing life-saving vaccines, and being critically malnourished.** The number is only expected to grow. Conflict drives approximately 80 per cent of all humanitarian needs around the world<sup>[2]</sup>, disrupting access to essentials, including safe water, food and healthcare.

**Over 473 million children—more than one in six globally—now live in areas affected by conflict<sup>[3]</sup>**, with the world experiencing the highest number of conflicts since World War II<sup>[4]</sup>. The percentage of the world's children living in conflict zones has doubled—from around 10 per cent in the 1990s to almost 19 per cent today.<sup>[5]</sup>

**By the end of 2023, 47.2 million children had been displaced due to conflict and violence<sup>[6]</sup>**, with trends in 2024 indicating additional displacement due to the intensification of conflicts, including in Haiti, Lebanon, Myanmar, the State of Palestine, and Sudan. Children account for 30 per cent of the global population, yet on average account for roughly 40 per cent of refugee populations and 49 per cent of internally displaced people.<sup>[7]</sup> In countries affected by conflict, on average over a third of the

population is poor (34.8 per cent) compared to just over 10 per cent in non-conflict-affected countries<sup>[8]</sup>.

"By almost every measure, 2024 has been one of the worst years on record for children in conflict in UNICEF's history—both in terms of the number of children affected and the level of impact on their lives," said UNICEF Executive Director Catherine Russell. "A child growing up in a conflict zone is far more likely to be out of school, malnourished, or forced from their home—too often repeatedly—compared to a child living in places of peace. This must not be the new normal. We cannot allow a generation of children to become collateral damage to the world's unchecked wars."...

**Conflicts are also having devastating effect on children's access to critical healthcare. Around forty per cent of un- and under-vaccinated children live in countries that are either partially or entirely affected by conflict.**<sup>[13]</sup> These children are often the most vulnerable to disease outbreaks like measles and polio, because of disruptions and lack of access to security, nutrition, and health services...

.....  
.....

## Sudan

### Sudan conflict – Situation in refugee-hosting countries, Multi-country External Situation Report #7, covering the reporting period November 2024

Edition 7 19 December 2024 | *WHO Emergency Situational Updates*

#### *Overview*

This is the seventh report summarizing the multi-country health situation and WHO's response to the regional refugee crisis caused by the conflict in Sudan. **Nearly 12.0 million people have been displaced—the largest number in the world—with almost 2.5 million displaced into neighbouring countries, including Chad, South Sudan, Egypt, Libya, Ethiopia, and the Central African Republic.**

As the Health Cluster Lead Agency, WHO ensures the coordination across partners and the strategic approach of the humanitarian health response. However, the existing funding gap limits the ability to scale up and address the needs.

Please note that this multi-country situation report focuses on the health situation and WHO's regional response in refugee-hosting, neighbouring countries neighbouring by the conflict Sudan. The health situation in Sudan and WHO's response is covered separately in reports issued by the WHO Sudan Country Office.

#### *Report excerpts*

##### **...Key operational challenges**

- **Resource Mobilization:** There remains a funding gap for the response to refugee-hosting countries' crises, significantly hampering operations.
- **Early Warning, Alert and Response (EWAR):** Inadequate early warning, alert and response surveillance among refugees hampers evidence-based decision-making.
- **Health Service Delivery:** Limited provision of health services at PoEs and in host communities due to overcrowding amongst refugees and large host populations, shortage of essential medical supplies and drugs (e.g., rapid diagnostic tests, antimalarial drugs), and direct/indirect damage to health facilities.
- **Health Worker Shortages:** Lack of health workers trained in emergency medical response, treatment of infectious diseases, surgery, public health emergency management and mental health.

- IPC/WASH: Limited availability of water and relevant supplies in refugee camps and health facilities, coupled with flooding in some refugee-hosting countries, are **increasing the risk of outbreaks (e.g., cholera, hepatitis E)**.
- **Insecurity: Ongoing hostilities between armed groups threaten the security on the ground, causing further displacement and adding challenges to infectious disease control and the delivery of medical countermeasures and humanitarian aid.**

### Next steps

- Continued support for health emergency preparedness and response work in refugee-hosting countries across different pillars, including surveillance, rapid response teams, WASH, case management, IPC, social and behaviour change, RCCE, medical countermeasures and supplies.
- Financial and logistical support to restock drug supplies, diagnostic kits, and IPC/WASH supplies at PoEs.
- Capacity building of health workers and EMTs at health facilities and PoEs serving host communities and refugees.
- Continued support to seven streams of sexual and reproductive health and rights (SRHR) activities to strengthen delivery systems of SRHR, including datasets for HIV, SRHR and gender-based violence.



## Cholera

# Multi-country outbreak of cholera



External Situation Report n. 21, published 18 December 2024

Cases – 733 956  
Since Jan. 2024

Deaths – 5162  
Since Jan. 2024

Countries affected – 33  
Since Jan. 2024

Population at risk  
1 billion

Global risk –  
Very high

## [Multi-country outbreak of cholera, External situation report #21 - 18 December 2024](#)

### Overview

Data as of 24 November 2024

- In November 2024 (epidemiological weeks 44 to 47), a total of 58 749 new cholera cases and acute watery diarrhoea (AWD) were reported from 21 countries, territories, areas (hereafter countries) across four WHO regions, marking a 2% decrease from October. The Eastern Mediterranean Region registered the highest number of cases, followed by the African Region, the South-East Asia Region, and the Region of the Americas. Additionally, 538 cholera-related deaths were reported globally, a 9% increase from the previous month.
- **The number of cases and deaths reported in November 2024 are 37% and 27% higher, respectively, compared to the same month in 2023.** The increase this year is largely due to updated data from Yemen, with adjustments made to account for more detailed information from regions outside the control of Yemen's Internationally Recognized Government. Yemen has retrospectively reported a total of 245 776 cases and 861 associated deaths across the country between 1 January and 24 November 2024.
- **Factors such as conflict, mass displacement, natural disasters, and climate change have intensified outbreaks, particularly in rural and flood-affected areas, where poor infrastructure and limited healthcare access delay treatment. These cross-border dynamics have made cholera outbreaks increasingly complex and harder to control.**



- **Since the last report, new cholera outbreaks have been reported in Cameroon, Mozambique, Uganda, and Zimbabwe.** The number of affected countries in 2024 remains unchanged at 33.
- From 1 January to 24 November 2024, a cumulative total of 733 956 cholera cases and 5162 deaths were reported from 33 countries across five WHO regions, with the Eastern Mediterranean Region recording the highest numbers, followed by the African Region, the South-East Asia Region, the Region of the Americas, and the European Region. No outbreaks were reported in the Western Pacific Region during this time.
- **In November, Oral Cholera Vaccines (OCV) production reached its highest level since 2013, driven by new formulations and production methods introduced and prequalified this year.**<sup>[1]</sup> This increase allowed the average stock to rise to 3.5 million doses in November compared to 600 000 in October, closer to the five million doses needed for emergency stockpile at all times for effective outbreak response. However, increased production has not met the rising global demand. This persistent shortage continues to hinder efforts to control cholera outbreaks and respond promptly to the disease's spread.

#### **Vaccination** [p.12]

- **The global stockpile averaged 3.5 million OCV doses in November, compared to the emergency target of five million doses that should be available at all times for outbreak response.**
- Twenty-eight new requests were received in 2024 from 15 countries: Bangladesh, Comoros, Ethiopia (3), Ghana (2), Kenya, Mozambique (2), Myanmar (2), Niger (2), Nigeria, Somalia, South Sudan (3), Sudan (6), Yemen, Zambia, and Zimbabwe, collectively seeking 47.7 million doses. Twenty-six were approved, one was not approved, one was cancelled by the International Coordinating Group (ICG) on Vaccine Provision.
- Since the start of 2024, 10 countries (Comoros, Ethiopia (4), Ghana (1), Mozambique (2), Myanmar, Niger, Nigeria, Somalia, South Sudan, Sudan (5), Zambia (2), and Zimbabwe (2)) have carried out 23 reactive vaccination campaigns in response to cholera outbreaks, targeting a total of 31 million people. **Given the current context of outbreaks and limited vaccine availability, only single dose vaccination courses have been validated and utilized in these reactive campaigns.**
- November marked the highest monthly OCV production since the global stockpile's creation in 2013, reflecting the efforts of the supplier and partners following the release and prequalification of a new vaccine formulation and manufacturing method earlier this year.
- **Despite these efforts, the limited supply of OCV doses continues to significantly hinder the capacity to conduct preventive vaccination campaigns.** This constrained global stockpile highlights the urgent need to scale up production and improve strategic stockpile management to meet both reactive and preventive vaccination needs effectively.

.....  
 .....

#### **mPox – PHEIC**

**[Multi-country outbreak of mpox, External situation report#44 - 23 December 2024](#)**



# Mpox

Multi-country external situation report no. 44, published 23 December 2024

KEY FIGURES				
Reporting period: 01 January 2022 – 30 November 2024				
Area	Number of reported confirmed cases	Number of deaths among confirmed cases	Number countries reporting cases	
Global	117 663	263	127	
Reporting period: 01 January – 15 December 2024				
Area	Number of reported confirmed cases	Number of deaths among confirmed cases	Number of reported suspected cases	Number of deaths among suspected cases
Africa	13 769	60	NA <sup>1</sup>	NA <sup>1</sup>
Democratic Republic of the Congo <sup>2,3</sup>	9 513	43	43 862	1138
Burundi	2 650	1	NA <sup>1</sup>	NA <sup>1</sup>
Uganda	1 027	6	NA <sup>1</sup>	NA <sup>1</sup>
Reporting period: last 6 weeks, 4 November – 15 December 2024				
Africa	1 904	7	NA <sup>1</sup>	NA <sup>1</sup>
Democratic Republic of the Congo <sup>2,3</sup>	137	0	3 046	38
Burundi	924	1	NA <sup>1</sup>	NA <sup>1</sup>
Uganda	681	5	NA <sup>1</sup>	NA <sup>1</sup>

## Highlights

- In November 2024, the last month for which of complete global surveillance global data are available, **2726 new confirmed mpox cases were reported**.
- Outside Africa, a high number of confirmed cases continued to be reported from Australia in November 2024. The country has been experiencing an unprecedented outbreak of clade IIb MPXV, affecting mainly men who have sex with men exposed primarily through sexual contact. In recent months though, there have been early indications of a plateau in monthly reported cases.
- The epidemiological situation in Africa remains especially concerning, and the high case counts continue to be driven by the outbreaks in the Democratic Republic of the Congo, Burundi, and Uganda.
- Clade Ib monkeypox virus (MPXV) has been detected in eight provinces in the Democratic Republic of the Congo: South Kivu, North Kivu, Kinshasa, Kasai, Tshopo, Tanganyika, Haut-Katanga, and Mai'Ndombe. This represents an increase of two provinces (Haut-Katanga and Mai'Ndombe) since the previous edition of this situation report.
- **Geographical expansion of clade Ib MPXV continues to be reported outside the Democratic Republic of the Congo, with Pakistan reporting its first recorded case of mpox due to clade Ib MPXV.**
- In addition to this, the Sultanate of Oman has reported its first recorded case of mpox due to clade I MPXV. Information on the MPXV subclade is not yet available.

[p.19]

## 5. Access to and delivery of countermeasures

### Vaccines

- **Several countries have accepted the allocation of mpox vaccine doses through the Access and Allocation mechanism (AAM) and shipment arrangements are under preparation.**
- The AAM partners are monitoring the progress of the allocation and delivery process to prevent stock expiry and continue to advocate for targeted vaccination in affected hotspots.
- **The current priority is to help countries improve their capacity to implement targeted vaccination with existing doses.**
- The AAM Supply Working Group (SWG) have established key performance indicators to streamline the vaccine allocation process.
- Countries are getting support to convert pledges into operational funds for implementation of the vaccination plans and strategies.
- **A total supply of 4 778 000 vaccines is available for future allocation to mpox-affected countries...**

.....

### **Gavi concludes agreements to facilitate donations of 305,000 mpox vaccine doses on behalf of US, with the first delivery to Nigeria**

20 December 2024

- Vaccines will be delivered to countries affected by the upsurge of mpox that continues to constitute a Public Health Emergency of International Concern (PHEIC). The first shipment of 11,200 doses arrived in Nigeria on 20 December
- Gavi CEO Dr Sania Nishtar: "We thank the US for these donations, which substantially strengthen the global mpox response. In addition to the 500,000 doses that Gavi procured directly in September through our First Response Fund, working with our donors, we now have legal frameworks in place to facilitate a substantial volume of additional pledged doses, which we will work with our partners to ensure are rolled out as quickly as possible"
- Other Gavi mpox outbreak support thus far includes emergency funding to the Democratic Republic of the Congo, Cameroon and Rwanda, and 500,000 directly procured vaccines alongside funding for delivery and other related costs

.....

.....

## **Polio – PHEIC**

### **Polio this week – 01 January 2025**

#### ***Headlines***

:: The Global Health Technologies Coalition (GHTC) recently honored the novel oral polio vaccine type 2 (nOPV2) development consortium with its 2024 Innovating for Impact Award. These awards, issued annually by GHTC, recognize multisectoral partnerships and policymakers helping to transform breakthrough scientific research into lifesaving drugs, diagnostics, vaccines, and other health tools for unmet global health challenges. [More](#).

#### **Summary of new polioviruses this week, cases and positive environmental isolates:**

- Pakistan: three WPV1 cases and 52 WPV1-positive environmental samples
- Algeria: one cVDPV2-positive environmental sample
- Côte d'Ivoire: four cVDPV2-positive environmental samples
- DR Congo: two cVDPV2 cases
- Poland: one cVDPV2-positive environmental sample
- South Sudan: one cVDPV2 case

.....

## **GPEI End-of-Year Letter 2024**

19/12/2024

What it will take to deliver a polio-free world

## **Poliovirus detections in European Region underscore importance of vaccination and vigilance**

13/12/2024

.....

.....

## **Public Consultations/Call for Inputs/Call for Papers**

### **Call for inputs for the comprehensive report, incl. new developments, in ensuring access to medicines, vaccines and other health products**

Issued by OHCHR

**Deadline 20 January 2025**

*Purpose:*

Consultation as per HRC resolution 50/13 and also to inform the comprehensive report on access to medicines, vaccines and other health products

*Background*

Human Rights Council resolution [50/13](#), requested the Office of the High Commissioner to prepare a comprehensive report, incl. new developments, in ensuring access to medicines, vaccines and other health products and to present it to the Council at its fifty-ninth session in June 2025.

.....

.....

### ***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

## **WHO & Regional Offices [to 03 Jan 2025]**

<https://www.who.int/news>

*Selected News/Announcements/Statements*

30 December 2024 *Statement*

**Milestone: COVID-19 five years ago**

28 December 2024 *Statement*

**Kamal Adwan Hospital out of service following a raid yesterday and repeated attacks since October**

26 December 2024 *Statement*

**Statement by Dr Tedros Adhanom Ghebreyesus, WHO Director-General on the attack on the Sana'a airport, Yemen**

23 December 2024 *Statement*

### **Statement on the antigen composition of COVID-19 vaccines**

*Key points:*

- Vaccination remains an important public health countermeasure against COVID-19. As per the WHO Director General's standing recommendations for COVID-19, Member States are recommended to continue to offer COVID-19 vaccination based on the recommendations of the WHO Strategic Advisory Group of Experts on Immunization (SAGE).
- SARS-CoV-2 continues to circulate and evolve with important genetic and antigenic evolution of the spike protein since the beginning of the COVID-19 pandemic.
- The objective of an update to COVID-19 vaccine antigen composition is to enhance vaccine-induced immune responses to circulating SARS-CoV-2 variants.
- The WHO TAG-CO-VAC advises retaining the use of a monovalent JN.1 lineage variant as the antigen in future formulations of COVID-19 vaccines.
- In accordance with WHO SAGE policy, vaccination should not be delayed in anticipation of access to vaccines with an updated composition; vaccination programmes can continue to use any available WHO emergency-use listed or prequalified COVID-19 vaccines.

20 December 2024 *News release*

### **Lebanon: soaring needs for trauma treatment and rehabilitation**

.....

### **WHO Regional Offices**

*Selected Press Releases, Announcements*

#### **WHO African Region AFRO**

:: **50 newly trained emergency responders join the Liberia AVoHC SURGE**

31 December 2024

:: **Strengthening Cholera Containment and Mpox Preparedness in Machinga District**

30 December 2024

:: **An mpox survivor's tale of hope**

22 December 2024

:: **Marburg outbreak in Rwanda declared over**

20 December 2024

:: **WHO Representative's remarks at celebration of end of Marburg Virus Disease outbreak in Rwanda**

20 December 2024

#### **WHO Region of the Americas PAHO**

:: 23 Dec 2024

**PAHO urges protection of medical facilities and services in Haiti to ensure continued access amid escalating conflict**

In 2024, the Organization delivered more than 38 tons of medical supplies and facilitated mobile clinics, in addition to supporting monitoring and water and sanitation activities to prevent cholera outbreaks. Port-au-Prince/Washington, DC, December 18, 2024 (PAHO) – As violence continues to escalate across Haiti, the Pan American Health...

:: 17 Dec 2024

**PAHO's year in health: 10 highlights from 2024**

In 2024, the Pan American Health Organization (PAHO) made significant strides in advancing health across the Americas, addressing both ongoing challenges and emerging health threats. These achievements highlight the collective efforts of governments, healthcare workers, communities, and partners working together to improve health outcomes for all...

## **WHO South-East Asia Region SEARO**

:: 16 December 2024 News release

**[Bolster efforts to end TB in WHO South-East Asia Region](#)**

## **WHO European Region EURO**

*Website not responding at inquiry.*

## **WHO Eastern Mediterranean Region EMRO**

*No new digest content identified.*

## **WHO Western Pacific Region**

*Website not responding at inquiry.*

.....

## **WHO - Emergency situation reports**

*Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.*

**[Multi-country outbreak of mpox, External situation report#44 - 23 December 2024](#)**

**[Sudan conflict – Situation in refugee-hosting countries, Multi-country External Situation Report #7, covering the reporting period November 2024](#)**

**[Multi-country outbreak of cholera, External situation report #21 - 18 December 2024](#)**

.....

## **Disease Outbreak News (DONs)**

*Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.*

**[27 December 2024 | Acute respiratory infections complicated by malaria \(previously undiagnosed disease\) - Democratic Republic of the Congo](#)**

**[20 December 2024 | Marburg virus disease - Rwanda](#)**

.....

## **Weekly Epidemiological Record**

<https://www.who.int/publications/journals/weekly-epidemiological-record>

**Vol. 99, Nos. 51/52, pp. 755–776 20 December 2024**

PDF: <https://iris.who.int/bitstream/handle/10665/379877/WER9951-52-eng-fre.pdf>

:: Global update on implementation of preventive chemotherapy against neglected tropical diseases (NTDs) in 2023 and status of donated medicines for NTDs in 2024

:: Progress in snakebite envenoming data reporting: challenges and opportunities

.....

## **New WHO Publications**

<https://www.who.int/publications/i>

*Selected*

25 December 2024

**[WHO SEAR 26th Epidemiological Bulletin 2024](#)**

20 December 2024

**[Global update on implementation of preventive chemotherapy against neglected tropical diseases \(NTDs\)...](#)**

20 December 2024

**[Workforce development for effective management of zoonotic diseases](#)**

19 December 2024

**[How to conduct a cross-sectional study of Middle East respiratory syndrome coronavirus infection in populations...](#)**

18 December 2024

**[Global report on infection prevention and control 2024: executive summary](#)**

*Overview*

This executive summary provides a synthesis of the second World Health Organization's Global report on infection prevention and control. Therefore, it highlights the updated evidence on the burden of infection and antimicrobial resistance and the related harm to both patients and health workers in health care settings. It presents an updated global situation analysis of the implementation of IPC programmes at the national and health care facility levels across all WHO regions.

While identifying key gaps and achievements at country and global level, the report sets priorities and offers guidance on the implementation of IPC interventions. Moreover, it highlights the importance of integration and alignment of IPC interventions with water, sanitation and hygiene strategies in the context of broader efforts to address AMR, health emergencies, and the quality and safety of health care.

16 December 2024

**[Guidance on evidence generation on new regimens for tuberculosis treatment](#)**

*Overview*

The Guidance on evidence generation (GEG) on new regimens for tuberculosis treatment is a first-of-its-kind document that advises researchers, developers, funders, and other stakeholders about how evidence should be generated to optimally inform WHO guideline development on novel regimens for TB treatment. It outlines 21 key messages, explains why they are important, and what approaches can increase the chances of research leading to strong WHO recommendations. The key messages cover areas such as trial design, selection criteria, outcome choice, sample size, analytic and economic considerations, and how to Investigate the impact of an intervention on health equity, acceptability, and feasibility.

16 December 2024

**[Fifteenth Meeting of the WHO South-East Asia Regional Immunization Technical Advisory Group](#)**

.....  
.....

**USA – HHS, FDA, CDC**

**HHS**

*News*

**[HHS awards \\$306 million in Avian Flu monitoring and preparedness funding](#)**

January 3, 2025 *News Release*

Today, the U.S. Department of Health and Human Services (HHS) announced it would award \$306 million dollars to continue its H5N1 Avian Flu response. While CDC's assessment of the risk of avian influenza to the general public remains low, USDA and HHS continue to closely collaborate with Federal, State, local, industry and other stakeholders to protect human health, animal health, and food safety.

"While the risk to humans remains low, we are always preparing for any possible scenario that could arise. These investments are critical to continuing our disease surveillance, laboratory testing, and monitoring efforts alongside our partners at USDA," said Secretary Xavier Becerra. "Preparedness is the key to keeping Americans healthy and our country safe. We will continue to ensure our response is strong, well equipped, and ready for whatever is needed."...

### **HHS Launches Let's Get Real Campaign to Highlight Facts About Childhood Vaccines and Share Stories from Confident Parents Who Vaccinate Their Kids**

December 20, 2024 News Release

*The campaign shares balanced information about vaccines and encourages parents to share why they trust vaccines to protect their children.*

Today, the U.S. Department of Health and Human Services' (HHS) launched the [Let's Get Real](#) campaign to cut through the noise of misinformation and give parents the balanced information they need about childhood vaccines. The campaign provides verifiable facts so parents can get the information they want to make informed vaccine decisions, and it shares stories from doctors and peers on why most of us rely on vaccines to protect our children. Let's Get Real also offers tools for health care professionals with pediatric patients...

### **FDA**

Press Announcements

*No new digest content identified.*

### **FDA VRBPAC**

Advisory Committee Calendar

*No new calendar dates identified.*

**CDC/ACIP [U.S.]** [to 03 Jan 2025]

<http://www.cdc.gov/media/index.html>

*Latest News*

### **CDC Confirms First Severe Case of H5N1 Bird Flu in the United States**

December 18, 2024-- A patient has been hospitalized with a severe case of avian influenza A(H5N1)Dec 18, 2024

### **ACIP Meetings**

*Next ACIP Meeting*

February 26-27, 2025

### **MMWR Weekly**

<https://www.cdc.gov/mmwr/index2024.html>

**December 19, 2024 / No. 50**

[PDF of this issue](#)

- [Surveillance of Human Adenovirus Types and the Impact of the COVID-19 Pandemic on Reporting — United States, 2017–2023](#)
- [Notes from the Field: Long COVID and Significant Long COVID–Associated Activity Limitation Among Adults, by Jurisdiction — United States, 2023](#)



- Notes from the Field: School-Based Surveillance of Mycoplasma pneumoniae Trends and Impact on School Attendance by Students and Staff Members — Missouri, Fall 2024

.....  
.....

## Europe

### European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

*News & Press Releases*

#### [A common EU approach to data transparency in medicine regulation](#)

EMA and HMA update principles for identification and disclosure of commercially confidential information and personal data

18 December 2024

EMA and HMA (Heads of Medicines Agencies) have published a comprehensive overhaul of their guidance on the identification of commercially confidential information (CCI) and personal data in marketing authorisation applications for human medicines. The update reaffirms the commitment of regulatory authorities across the European Economic Area (EEA) to extensive transparency when disclosing information, both in response to access-to-documents requests and in the proactive publication of data once a medicine is authorised...

#### [Emer Cooke, EMA's Executive Director: 2024 achievements in medicine regulation](#)

EMA's Executive Director shares her end-of-year message and takes stock of EMA's work in 2024  
17 December 2024

### European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

*News/Updates/Reports/Publications [Selected]*

#### [Acute respiratory infections in the EU/EEA: epidemiological update and current public health recommendations – winter 2024/2025](#)

18 Dec 2024

*Surveillance and monitoring*

#### [Communicable disease threats report, 14-20 December 2024, week 51](#)

20 Dec 2024

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 14-20 December 2024 and includes updates on Cyclone Chido, Mpox due to monkeypox virus clade I and II, SARS-CoV-2 variant classification, Overview of respiratory virus epidemiology in the EU/EEA, Marburg virus disease and Avian influenza A(H5N1).

*Surveillance and monitoring*

#### [Avian influenza overview September-December 2024](#)

18 Dec 2024

Between 21 September and 6 December 2024, 657 highly pathogenic avian influenza virus detections were reported in domestic (341) and wild (316) birds across 27 countries in Europe.

.....  
.....

### Africa CDC [to 03 Jan 2025]

<https://africacdc.org/>

*Press Releases, Statements [Selected]*

### **Africa CDC Applauds Egypt's Milestone Achievement in Medicines and Vaccine Regulation**

Addis Ababa, Ethiopia – 22 December 2024 – The Africa Centres for Disease Control and Prevention (Africa CDC) congratulates the Egyptian Drug Authority (EDA) on its historic milestone of earning the WHO's Maturity Level 3 (ML3) designation for medicines regulation, marking Egypt as the first African nation to achieve this status for both medicines and vaccine regulation. This remarkable milestone highlights Egypt's leadership in advancing regulatory excellence and strengthening health security across the continent.

H.E. Dr. Jean Kaseya, Director General of Africa CDC, commended the Egyptian government and the EDA, stating, "Egypt's accomplishment is a source of immense pride—not only for the country but for the entire continent. It marks a significant step forward in advancing the African Union's Agenda 2063 and promoting health equity. This achievement underscores the transformative power of investing in robust regulatory systems, which are critical for ensuring access to quality, safe, and effective medical products."

While celebrating this progress, Africa CDC emphasizes that Africa remains the only continent without a regulatory authority that has achieved WHO Maturity Level 4 (ML4)—the highest standard in regulatory excellence. This gap underscores the urgent need to enhance Africa's capacity to independently ensure the safety, efficacy, and quality of high-risk medical products. Closing this gap is critical for bolstering the continent's health security and resilience...

*Op-Ed*

### **The Hidden Pandemic Threatening Africa's Progress**

16 December 2024

*... A Call to Action*

Antimicrobial resistance is one of the greatest health crises of our time, threatening to erase decades of progress in global health. However, with strong leadership, strategic investments and global collaboration, Africa can turn the tide.

Malawi's success demonstrates the transformative impact of unified efforts. By prioritising infrastructure, capacity building and interventions such as WASH, the continent can protect its people and sustain its progress.

The stakes are high, but the solutions are clear. Through collective action and unwavering commitment, we can combat AMR and secure a healthier, more resilient future for Africa and the world

.....

### **China CDC+**

<http://www.chinacdc.cn/en/>

### **National Health Commission of the People's Republic of China [to 03 Jan 2025]**

<http://en.nhc.gov.cn/>

*News*

*No new digest content identified.*

### **National Medical Products Administration – PRC [to 03 Jan 2025]**

<http://english.nmpa.gov.cn/>

*News*

*No new digest content identified.*

### **China CDC**

### **CCDC Weekly Reports: Current Volume (7)**

**2025-01-03 / No. 1**

[PDF of this issue](#)

- [Preplanned Studies: Assessment of the Public Health Laboratory Capacity — Sierra Leone, 2021](#)
- [Recollection: China-UK Global Health Collaboration Project on Strengthening Public Health Capacity in Sierra Leone](#)

## **2024-12-13 / No. 50 WORLD STRENGTHENED IMMUNIZATION DAY ISSUE**

[PDF of this issue](#)

- [Vital Surveillances: Surveillance for Adverse Events Following Immunization with Domestic Sabin-Strain Inactivated Poliovirus Vaccine — China, 2015–2022](#)
- [Vital Surveillances: Impact of Immunization Strategies on Rubella Incidence During Progress Toward Rubella Control and Elimination — China, 2004–2023](#)
- [Preplanned Studies: Post-Marketing Surveillance of Adverse Events Following Meningococcal Vaccination — China, 2013–2021](#)
- [Preplanned Studies: Immunogenicity of Short-Course, High-Dose Hepatitis B Vaccination in Patients with Chronic Kidney Disease — Shanxi Province, China, 2019–2020](#)
- [Methods and Applications: Cost-Effectiveness Analysis of Vaccination Compliance Strategies Using a Novel Hybrid Model for Influenza Vaccination](#)
- [Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, September 2024\\*](#)
- [Commentary \(Commemoration\): In Memoriam of Professor Hans Wolf](#)

.....  
.....

### ***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....  
.....

### ***Organization Announcements***

**Paul G. Allen Frontiers Group** [to 03 Jan 2025]

<https://alleninstitute.org/news-press/>

*News*

#### **[Allen Institute announces 2024 Next Generation Leaders](#)**

12.19.2024

Fostering collaboration and innovation from emerging leaders in bioscience

*In the News*

#### **[Tech Moves: Allen Institute names new VP](#)**

12.17.2024

Julie Harris has been appointed vice president of The Paul G. Allen Frontiers Group at the Seattle-based Allen Institute.

**BMGF - Gates Foundation** [to 03 Jan 2025]

<https://www.gatesfoundation.org/ideas/media-center>

*Press Releases & Statements*

## **Statement from Gates Foundation CEO Mark Suzman: On President Jimmy Carter**

*Press release* Dec 29, 2024

President Jimmy Carter was ...a tireless leader who never stopped changing lives for the better. For close to three decades, President Carter, Rosalynn Carter, and The Carter Center led the fight against neglected tropical diseases (NTDs) that plague those living in poverty. Thanks to the Carter Center's extraordinary health programs conducted in partnership with countries' health ministries and health workers, hundreds of millions of people have been able to access medicine to prevent NTDs, and dozens of countries have been able to eliminate at least one of these diseases altogether. This would not have been possible without President Carter's vision and his efforts to galvanize action against these diseases...

## **Bill & Melinda Gates Medical Research Institute** [to 03 Jan 2025]

<https://www.gatesmri.org/news>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

*News: Articles and Publications*

*No new digest content identified.*

## **CARB-X** [to 03 Jan 2025]

<https://carb-x.org/>

*News*

*No new digest content identified.*

## **CEPI – Coalition for Epidemic Preparedness Innovations** [to 03 Jan 2025]

<http://cepi.net/>

*CEPI News*

*News*

## **Richard Hatchett reflects on a “banner year for viruses” and looks ahead to 2025**

19 Dec 2024

*News*

## **Valneva expands access to Asia for its chikungunya vaccine with Serum**

18 Dec 2024

...Supported by CEPI and the European Union (EU)'s Horizon program, Valneva remains focused on expanding the vaccine's access in LMICs. Under an earlier funding agreement with CEPI [5]. Valneva partnered with Brazil's Instituto Butantan (IB) to expand access to the vaccine in the Americas. Review of the marketing authorization application by the Brazilian Health Regulatory Agency (ANVISA) is ongoing...

*News*

## **Establishing vaccine safety benchmarking in Africa for African vaccines**

16 December 2024: A research consortium is set to further establish a vaccine safety evidence-generation network in Africa, seeking to understand the general prevalence of anticipated adverse events specifically relevant to African populations.

CEPI is providing up to US\$9.9 million for the Background Rates of Adverse Events for Vaccine Evaluation in Africa project led by the Global Vaccine Data Network (GVDN)—based at Auckland UniServices Limited in the University of Auckland—in partnership with the University of the

Witwatersrand in South Africa, Navrongo Health Research Center in Ghana, International Foundation Against Infectious Diseases in Nigeria, Eagle Research Center in Rwanda, and Health Research Operations Kenya (operating as KEMRI-Wellcome Trust Research Programme) in Kenya. CEPI funds will support local researchers across these research sites to understand incidence rates of naturally occurring clinical events, such as Guillain-Barré Syndrome, sensorineural hearing loss, and others, that typically occur in African populations (i.e., without any medical interventions).

With this baseline data, or background rates, researchers in Africa will then be able to evaluate whether an adverse event reported in a vaccine trial may be associated with the vaccine—an adverse event of special interest (AESI)—or is coincidental and occurs at a rate within expected background levels in the general population. This comprehensive monitoring—specific to African populations—helps set expectations for what might be expected when the vaccine is rolled out more widely, minimising the risk of trials being halted or public confidence in the vaccines being undermined. Crucially, this data enables regulatory authorities to make informed decisions about vaccine safety on its path to approval and roll-out...

### **CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 03 Jan 2025]

<https://cioms.ch/>

*News; Publications; Events*

*No new digest content identified.*

### **DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 03 Jan 2025]

<https://www.darpa.mil/news>

*News*

*No new digest content identified.*

### **DNDI – Drugs for Neglected Diseases initiative** [to 03 Jan 2025]

<https://dndi.org/press/press-releases/>

*Press Releases*

*No new digest content identified.*

### **Duke Global Health Innovation Center** [to 03 Jan 2025]

<https://dukeghic.org/>

*News*

#### **The COVID Treatment QuickStart Consortium Newsletter: December 2024 Edition**

This newsletter aims to provide a central hub for information, milestones, and updates regarding the COVID Treatment QuickStart Consortium. The COVID Treatment QuickStart Consortium partners with governments to rapidly introduce and scale access to COVID-19 oral antiviral therapies in vulnerable and high-risk populations presenting with mild to moderate symptoms within five days of symptom onset through a public health test-and-treat model.

December 18, 2024

### **EDCTP** [to 03 Jan 2025]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS,*

*tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*  
*No new digest content identified.*

**Emory Vaccine Center** [to 03 Jan 2025]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Vaccine Initiative** [to 03 Jan 2025]

<http://www.euvaccine.eu/>

*Latest News, Events*

*No new digest content identified.*

**Fondation Merieux** [to 03 Jan 2025]

<http://www.fondation-merieux.org/>

*News, Events*

*No new digest content identified.*

**Gavi** [to 03 Jan 2025]

<https://www.gavi.org/>

*Press Releases*

20 December 2024

**[Gavi concludes agreements to facilitate donations of 305,000 mpox vaccine doses on behalf of US, with the first delivery to Nigeria](#)**

- Vaccines will be delivered to countries affected by the upsurge of mpox that continues to constitute a Public Health Emergency of International Concern (PHEIC). The first shipment of 11,200 doses arrived in Nigeria on 20 December
- Gavi CEO Dr Sania Nishtar: "We thank the US for these donations, which substantially strengthen the global mpox response. In addition to the 500,000 doses that Gavi procured directly in September through our First Response Fund, working with our donors, we now have legal frameworks in place to facilitate a substantial volume of additional pledged doses, which we will work with our partners to ensure are rolled out as quickly as possible"
- Other Gavi mpox outbreak support thus far includes emergency funding to the Democratic Republic of the Congo, Cameroon and Rwanda, and 500,000 directly procured vaccines alongside funding for delivery and other related costs

**GE2P2 Global Foundation** [to 03 Jan 2025]

[www.ge2p2.org](http://www.ge2p2.org)

*News/Analysis/Publications-Digests/Statements*

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – January 2025](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 11 Dec 2024 – Issue 26](#)

**GHIT Fund** [to 03 Jan 2025]

<https://www.ghitfund.org/newsroom/press>

## *Press Releases*

December 11, 2024

### **Partnership established to advance WHO's Road map for Neglected Tropical Diseases 2021-2030**

The Global Health Innovative Technology (GHIT) Fund and the World Health Organization (WHO) have signed a memorandum of understanding (MoU) to further expand their partnership to promote access to safe, effective and affordable drugs, vaccines and diagnostics in the area of neglected tropical diseases (NTDs).

The MoU makes provision for four areas of collaboration: (i) research and development aimed at strengthening the arsenal of innovative tools, treatments and interventions for NTDs; (ii) resource mobilization, notably through the development of an NTD investment case toolkit and sustainable procurement systems; (iii) advocacy and awareness, to raise the profile of NTDs within global and local health agendas; and (iv) participation of GHIT as observers in NTD working groups and task forces convened by WHO...

**Global Fund** [to 03 Jan 2025]

<https://www.theglobalfund.org/en/news/>

## *News Releases*

17 December 2024

### **Global Fund, PEPFAR Announce Coordinated Effort to Reach 2 Million People with Lenacapavir for PrEP to Significantly Reduce Global HIV Infections**

GENEVA | WASHINGTON D.C. – The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) and the United States President's Emergency Plan for AIDS Relief (PEPFAR) have joined forces with the Children's Investment Fund Foundation (CIFF) and the Bill & Melinda Gates Foundation (BMGF) to announce today a coordinated effort that will rapidly provide affordable and equitable access to twice-yearly injectable lenacapavir for HIV pre-exposure prophylaxis (PrEP) contingent upon regulatory approval from the U.S. Food and Drug Administration, relevant national pharmaceutical regulators, and a recommendation from the World Health Organization (WHO).

The Global Fund and PEPFAR are aiming to secure sustainable arrangements for countries to access this new, potentially game-changing HIV prevention innovation – backed by a significant commitment from CIFF, and with support from BMGF – that would enable access to lenacapavir for at least 2 million people over three years in countries supported by PEPFAR and the Global Fund.

Gilead Sciences' lenacapavir is already approved in multiple countries to treat adults with multidrug-resistant HIV in combination with other antiretroviral drugs. Recent and highly promising clinical trial results show its potential in preventing new HIV infections as well. If rolled out at scale alongside other HIV prevention tools, including daily oral antiretroviral medications already approved for PrEP, lenacapavir has the potential to accelerate progress toward the 2030 Sustainable Development Goal 3 HIV target of ending HIV/AIDS as a public health threat, as well as ensuring a sustainable HIV response beyond 2030.

In October 2024, Gilead announced that it had signed non-exclusive, royalty-free voluntary licensing with six pharmaceutical companies to manufacture and supply high-quality, low-cost versions of lenacapavir for HIV prevention for 120 primarily low- and lower-middle-income countries...

16 December 2024

### **Germany and Indonesia Sign Landmark €75 Million Debt Conversion Agreement to Strengthen Public Health**

JAKARTA, INDONESIA – The Federal Republic of Germany and the Republic of Indonesia, with support from the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund), have signed a landmark Debt2Health agreement, converting €75 million of Indonesia's debt into transformative investments for public health. This agreement represents the largest Debt2Health swap to date and will



significantly enhance Indonesia's ability to combat infectious diseases and strengthen its health systems.

The converted funds will support malaria control efforts, enhance health system infrastructure, and promote local production of medicines. These initiatives are designed to improve diagnostic capabilities and build more resilient health systems across the country.

An additional focus will be placed on Indonesia's fight against tuberculosis (TB); the country has the second-largest TB burden in the world. The investments will be used to procure essential diagnostic tools and medicines, strengthen screening capacities and expand community outreach and public-private programs aimed at TB prevention and care.

The Debt2Health initiative, launched by the Global Fund, provides a unique financing mechanism that allows countries to transform debt into investments in national health priorities...

### **Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 03 Jan 2025]

<https://www.glopid-r.org/news/>

*News*

#### **GloPID-R and CORC Cooperate to Strengthen Pandemic Preparedness and Response**

December 13, 2024

The Global Research Collaboration for Infectious Disease Preparedness (GloPID-R) and the World Health Organization (WHO) have agreed to cooperate through WHO's Collaborative Open Research Consortium (CORC) initiative to enhance global efforts in pandemic preparedness and response.

### **Hilleman Laboratories** [to 03 Jan 2025]

<http://www.hilleman-labs.org/>

*News & Insights*

*No new digest content identified.*

### **HHMI - Howard Hughes Medical Institute** [to 03 Jan 2025]

<https://www.hhmi.org/news>

*Press Room*

*No new digest content identified.*

### **Human Immunome Project [nee Human Vaccines Project]** [to 03 Jan 2025]

<https://www.humanimmunomeproject.org/>

*News*

*No new digest content identified.*

### **IAVI** [to 03 Jan 2025]

<https://www.iavi.org/>

*Press Releases*

*Features*

#### **Access to monoclonal antibodies in Africa: A call to action**

December 17, 2024

*IAVI and Impact Global Health issue a renewed call to action to ensure equitable access to monoclonal antibodies.*

IAVI and Impact Global Health today published a new report evaluating the current state of research and development (R&D) and access for monoclonal antibodies (mAbs) and related products. The

report, funded by Wellcome, is a four-year retrospective on the availability of mAbs and biosimilars globally — with new insights into the African region that could serve as a bellwether for progress globally.

This is the second global call to action IAVI and our partners have published toward improving mAbs access in low- and middle-income countries. The first was an [IAVI-Wellcome joint report](#) published in 2020 when just over 650 mAbs were in development for various medical conditions. Of the 570 mAbs in clinical testing in 2020, more than 60% targeted oncology indications. As of 2024, the clinical pipeline has nearly doubled to include more than 1,000 innovative candidates, with cancer mAbs still dominating the landscape...

The report concludes that while progress has been made in developing and approving mAbs in the past four years, more is needed to make mAbs accessible to all. Our renewed call to action provides specific recommendations for priority stakeholders — such as governments, health care providers, pharmaceutical companies, the private sector, funders, civil society, and international organizations — to develop innovative, scalable, and cost-effective models for mAbs R&D, manufacturing, and access tailored to the unique needs in different geographies...

**INSERM** [to 03 Jan 2025]

<https://www.inserm.fr/en/home/>

*Press Releases*

*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

**ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use]** [to 03 Jan 2025]

<https://www.ich.org/>

*News/Pubs/Press Releases [Selective]*

*No new digest content identified.*

**ICRC** [to 03 Jan 2025]

<https://www.icrc.org/en/whats-new>

*What's New [Selected]*

[Frequently asked questions on the ICRC's work in Syria](#)

*Article 01-01-2025*

[Israel and the Occupied Territories: Obliteration of health care system in northern Gaza puts civilians at grave risk](#)

*News release 30-12-2024*

[Red Cross Field Hospital in Rafah, Gaza Strip: Facts & Figures December 2024](#)

*Article 24-12-2024*

**IFFIm**

<http://www.iffim.org/>

*Press Releases/Announcements*  
*No new digest content identified.*

**IFRC** [to 03 Jan 2025]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Press Releases [Selected]*

*Press release 26/12/2024*

**[Red Cross responds to cyclone Chido and scales up preparedness for future storms as initial assessments paint a grim picture](#)**

*Press release 23/12/2024*

**[IFRC pledges support for five million people in Syria as they return to destroyed homes and neighbourhoods](#)**

*Press release 20/12/2024*

**[Vanuatu earthquake: A nation in crisis highlights urgent need for community-based preparedness](#)**

*Press release 19/12/2024*

**[Red Cross Amazon Alliance aims to safeguard lives and strengthen community resilience](#)**

**Institut Pasteur** [to 03 Jan 2025]

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*Press Info 06.12.2024*

**[From Yemen to Mayotte, the spread of a highly drug-resistant cholera strain](#)**

Scientists from the National Reference Center for Vibrios and Cholera at the Institut Pasteur, in collaboration with the Centre hospitalier de Mayotte, have revealed the spread of a highly drug-resistant cholera strain. The study was published on December 12, 2024 in the [New England Journal of Medicine](#).

**ISC / International Science Council** [to 03 Jan 2025]

<https://council.science/current/>

*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

*Latest Updates*

*No new digest content identified.*

**International Union of Immunological Societies (IUIS)**

<https://iuis.org/>

*News/Events [Selected]*

*No new digest content identified.*

**IVAC** [to 03 Jan 2025]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

December 18, 2024

## **Suboptimal Vaccination Rates Leave Children, Older Adults Susceptible to Respiratory Illness**

**IVI** [to 03 Jan 2025]

<http://www.ivi.int/>

*IVI News & Announcements*

### **2024 Year in Review**

*[Undated]*

At the end of 2024, we reflect on the milestones and accomplishments from across the institute that made this year particularly memorable. We dedicate this 2024 Year in Review to our collaborators and partners around the world whose support makes our work possible.

We are pleased to share 12 highlights from IVI, which include two new vaccines prequalified by the World Health Organization for use in global public health settings; new work on IVI's "Vaccine #4," a vaccine against *K. pneumoniae*, the leading cause of neonatal deaths globally due to sepsis; the start of a multi-country initiative to advance research capacity in West Africa; new state parties (Austria, El Salvador, and Kenya); expanded offices worldwide, from the official opening of the IVI Europe Regional Office permanent location to the signing of a Host Country Agreement with the Government of Rwanda; and more.

## **Advancing research capacity and pandemic preparedness in West Africa**

16 Dec 2024

The Advancing Research Capacity in West Africa (ARC-WA) project led by IVI and Medical Research Council Unit The Gambia (MRCG) at the London School of Hygiene & Tropical Medicine has two distinct but inter-connected aims to ensure the West African sub-region is equipped to deal with the threat of endemic diseases like Lassa fever and both known and unknown outbreak diseases:

1. Preparing clinical trial sites for Phase 2b and Phase 3 Lassa fever vaccine clinical trials in Lassa fever-endemic West African countries
2. Developing and advancing regional strategies to rapidly generate clinical evidence around vaccines and other biological countermeasures during emergencies

**Johns Hopkins Center for Health Security** [to 03 Jan 2025]

<https://centerforhealthsecurity.org/newsroom>

*Center News [Selected]*

*No new digest content identified.*

**MSF/Médecins Sans Frontières** [to 03 Jan 2025]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Gaza-Israel war*

## **Babies in Gaza at risk of disease and death as winter approaches**

2 Jan 2025

*India*

## **MSF hands over drug-resistant tuberculosis project in Mumbai after 18 years**

24 Dec 2024

**National Academy of Medicine** - USA [to 03 Jan 2025]

<https://nam.edu/programs/>

*News [Selected]*

**[NAM Paper Presents Shared Commitments to Increase Performance and Trust in the U.S. Health System](#)**

December 16, 2024

Prompted by a persistent mismatch between high health expenditures and shortfalls in safety, quality, and health outcomes in the United States, the National Academy of Medicine (NAM) has been shepherding [...]

**National Academies-Sciences-Engineering-Medicine [NASEM]- USA** [to 03 Jan 2025]

<https://www.nationalacademies.org/newsroom>

*News*

**[Science Misinformation, Its Origins and Impacts, and Mitigation Strategies Examined in New Report; Multisector Action Needed to Increase Visibility of, Access to High-Quality Science Information](#)**

Over the last decade, concerns about the spread of misinformation about science and the role of scientific expertise in civic dialogue have grown significantly. A new National Academies report provides a comprehensive assessment of the literature on science misinformation and strategies for mitigating its spread and potential harms.

2024-12-19

**National Vaccine Program Office - U.S. HHS** [to 03 Jan 2025]

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

*No new digest content identified.*

**NIH** [to 03 Jan 2025]

<http://www.nih.gov/>

*News Releases*

**[NIH officials assess threat of H5N1](#)**

December 31, 2024 —

Balancing enhanced vigilance and “business as usual.”

**PATH** [to 03 Jan 2025]

<https://www.path.org/media-center/>

*Newsroom*

*No new digest content identified.*

**Sabin Vaccine Institute** [to 03 Jan 2025]

<https://www.sabin.org/press/>

*Latest News & Press Releases*

*Press Releases*

**[Organization of African First Ladies for Development Signs Agreement with Sabin Vaccine Institute to Develop Cervical Cancer Elimination Strategy](#)**

December 19, 2024

Washington, D.C. – The Organization of African First Ladies for Development (OAFLAD) and Sabin Vaccine Institute, on behalf of the Global HPV Consortium, have entered into a three-year agreement

to advance action towards HPV prevention and cervical cancer elimination on the African continent. This was an agreement as result of the decision of the highest decision making organ of the OAFLAD which is 28th OAFLAD General Assembly...

**UNAIDS** [to 03 Jan 2025]

<http://www.unaids.org/en>

*News, Stories, Updates*

*Feature story*

**Efforts to end AIDS in children receive major boost with the launch of the first provincial chapter of the Global Alliance in Eastern Cape Province, South Africa**

23 December 2024

South Africa's fight to end AIDS in children has received a major boost with the launch of the first provincial Global Alliance chapter in the Eastern Cape province. The Global Alliance is driving a global agenda to end AIDS in children by 2030 together with UNAIDS, the Joint United Nations Programme responsible for the global HIV and AIDS response, with a commitment to ensure that all children who are already living with HIV are on lifesaving treatment to live long and healthy lives and to prevent new HIV infections in newborns.

**UNICEF** [to 03 Jan 2025]

<https://www.unicef.org/media/press-releases>

*Latest press releases, news notes and statements*

*Press release 28 December 2024*

**'Not the new normal' – 2024 'one of the worst years in UNICEF's history' for children in conflict**

NEW YORK, 28 December 2024 – The impact of armed conflicts on children around the world reached devastating and likely record levels in 2024, according to a review by UNICEF of the latest available data and prevailing global trends. More children than ever are estimated to be either living in conflict zones or for...

*Statement 26 December 2024*

**Statement by UNICEF Regional Director for the Middle East and North Africa Edouard Beigbeder on continued deaths of children in Gaza**

AMMAN, 26 December 2024 – "In the final days of the year, there seems to be no end in sight to the deadly threats to children in Gaza. Over the past three days, at least eleven children have reportedly been killed in attacks. Now, we are also witnessing children dying from the cold and a lack of adequate shelter. ...

*Press release 24 December 2024*

**Food and nutrition crisis deepens across Sudan as famine identified in additional areas**

ROME/NEW YORK, 24 December 2024 – Four months after famine was first confirmed in Zamzam camp in Sudan's North Darfur state, more areas in North Darfur and the Western Nuba mountains have been identified as experiencing famine conditions, as access to food and nutrition for millions of people across the country co...

*Remarks 20 December 2024*

**"Cold, sick and traumatized" - the ongoing nightmare for children in Gaza**

AMMAN/GENEVA, 20 December 2024 – "Children in Gaza are cold, sick and traumatized. Hunger and malnutrition, and the dire living conditions more broadly, continue to put the lives of children at risk. Right now, over 96% of women and children in Gaza cannot meet their basic nutritional needs. Most are surviving on ...

*Statement* 18 December 2024

**Peace must prevail for Syria's children**

DAMASCUS, 17 December 2024 - "Today, I concluded my visit to Damascus, Homs, Hama, Aleppo and Idlib where I witnessed the dire situation for Syria's children. After 14 years of war, millions of children have known nothing but conflict, forcing them to grow up far too quickly. Yet there is hope and an opportunity f...

**Unitaid** [to 03 Jan 2025]

<https://unitaid.org/>

*Featured News*

*No new digest content identified.*

**Vaccine Equity Cooperative [nee Initiative]** [to 03 Jan 2025]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 03 Jan 2025]

<https://www.vaccineacceptance.org/>

*No new digest content identified.*

**Vaccine Confidence Project** [to 03 Jan 2025]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

*No new digest content identified.*

**Vaccine Education Center – Children's Hospital of Philadelphia** [to 03 Jan 2025]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

*No new digest content identified.*

**Wellcome Trust** [to 03 Jan 2025]

<https://wellcome.org/news/all>

*News. Opinion, Reports*

*News*

Authors: Luigi Martino, Marion Mercier

**Unblocking barriers to progress in bioimaging**

19 December 2024

**The Wistar Institute** [to 03 Jan 2025]

<https://www.wistar.org/news/press-releases>

*Press Releases*

*No new digest content identified.*



**World Bank** [to 03 Jan 2025]

<http://www.worldbank.org/en/news/all>

*All News [Selected]*

**The Pandemic Fund Announces Third Round of Funding, Marking Another Milestone in Pandemic Preparedness**

Washington, D.C., December 19, 2024 — The Pandemic Fund's Governing Board approved a grant envelope of \$500 million for its third round of funding to help low- and middle-income countries...

Date: December 19, 2024 Type: Press Release

**Integration of Migrants, Refugees, and Returnees: A Driver for Improving Well-being and the Economy**

Published for the first time in Revista Summa. Did you know that the well-being generated by the gains from crossborder mobility far outweigh those from trade liberalization? This is because facilitating...

Date: December 16, 2024 Type: Opinion

**WFPHA: World Federation of Public Health Associations** [to 03 Jan 2025]

<https://www.wfpha.org/>

*Blog, Events*

*No new digest content identified.*

**World Medical Association [WMA]** [to 03 Jan 2025]

<https://www.wma.net/news-press/press-releases/>

*Press Releases*

**The World Medical Association remains deeply concerned about the International Federation of Medical Students Association's suspension of its Israeli member organization**

1G7.12.2024

**World Organisation for Animal Health [OIE]** [to 03 Jan 2025]

<https://www.oie.int/>

*Press Releases, Statements*

*No new digest content identified.*

.....

.....

**ARM [Alliance for Regenerative Medicine]** [to 03 Jan 2025]

<https://alliancerm.org/press-releases/>

*Selected Press Releases*

*No new digest content identified.*

**BIO** [to 03 Jan 2025]

<https://www.bio.org/press-releases>

*Press Releases*

*No new digest announcements identified.*

## **DCVMN – Developing Country Vaccine Manufacturers Network** [to 03 Jan 2025]

<http://www.dcvmn.org/>

*News; Upcoming events*

*No new digest announcements identified.*

## **ICBA – International Council of Biotechnology Associations** [to 03 Jan 2025]

<https://internationalbiotech.org/news/>

*News*

*No new digest announcements identified.*

## **IFPMA** [to 03 Jan 2025]

<https://ifpma.org/>

*News, Statements [Selected]*

*External study 19 December 2024*

### **Global regulatory approaches to post-approval changes in biotherapeutic products**

*IFPMA worked with Clarivate to study how different countries and regions approach the regulation of post-approval changes (PACs) in biotherapeutic products.*

The research compared PACs guidelines across 21 countries and regions in Latin America (LATAM), Asia-Pacific (APAC), and the Middle East and Africa (MEA) to the World Health Organization (WHO) Guidelines on changes on biotherapeutic products.

The findings reveal significant diversity in the level of convergence among countries and with the WHO, with a few notable trends.

*Key recommendations*

- Global regulatory convergence using a science and risk-based regulatory framework enables more efficient management of PACs, especially when specifically adapted to biologics (and other modalities)
- Establishing national or regional variation guidelines in line with international standards (e.g. WHO, ICH Q12) in terms of categorization, requirements and timelines allows predictability and consistency in the handling of changes without the need for additional local requirements
- Expanding reliance practices to include life cycle management will accelerate the approval of changes, facilitating patient access to innovative, high-quality, and safe products.

## **International Alliance of Patients' Organizations – IAPO** [to 03 Jan 2025]

<https://www.iapo.org.uk/news>

*Press and media [Selected]*

*No new digest announcements identified.*

## **International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

### **Lucas Sigman and Allan Oberman appointed 2025 Chair and Vice-Chair of the IGBA CEO Advisory Committee**

Geneva, 19 December 2024

The International Generic and Biosimilar medicines Association (IGBA) announced today the annual leadership change of its CEO Advisory Committee (AC). Lucas Sigman, CEO of Insud Pharma, has been appointed Chair and Allan Oberman, President and CEO of Apotex, Vice-Chair.

The CEO AC is composed of fifteen leading multinational companies from Canada, Europe, India, Israel, Japan and the United States. This Committee provides a forum for industry leaders to discuss broad, strategic issues, and to engage and position the industry on a range of critical policy issues...

**PhRMA** [to 03 Jan 2025]

<http://www.phrma.org/>

*Press Releases*

*No new digest announcements identified.*

.....

.....

### ***Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements***

#### **AstraZeneca**

*Press Releases* - No new digest announcements identified

#### **Bavarian Nordic**

*Latest News*

December 16, 2024

[\*\*Bavarian Nordic Enters License and Manufacturing Agreement for its Mpox Vaccine with Serum Institute of India\*\*](#)

#### **Bharat Biotech**

*Press Releases* - No new digest announcements identified

#### **BioCubaFarma – Cuba**

*Últimas Noticias* - No new digest announcements identified

#### **Biological E**

*News* - No new digest announcements identified

#### **BioNTech**

*Press Releases* - No new digest announcements identified.

#### **Boehringer**

*Press Releases* - No new digest announcements identified.

#### **CanSinoBIO**

*News* - Website not responding at inquiry

#### **CIGB**

*Latest News* - No new digest announcements identified.

#### **Cinnagen**

*Recent News* - No new digest announcements identified.

#### **Clover Biopharmaceuticals – China**

*News* - No new digest announcements identified.

#### **Curevac**

News - No new digest announcements identified.

## **Gamaleya National Center/Sputnik**

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

## **GSK**

Press releases for media

16 December 2024

[ViiV Healthcare announces CHMP positive opinion for Vocabria + Rekambys, the first and only complete long-acting HIV treatment, for adolescents in Europe](#)

## **EuBiologics, S Korea**

News - No new digest announcements identified.

## **IMBCAMS, China**

Home - Website not responding at inquiry.

## **Janssen/JNJ**

Press Releases - No new digest announcements identified.

## **Merck**

News releases

[Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir \(DOR/ISL\) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection](#)

December 19, 2024

[Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season](#)

December 19, 2024

## **Moderna**

Press Releases - No new digest announcements identified

## **Nanogen**

News - No new digest announcements identified

## **Novartis**

News - No new digest announcements identified.

## **Novavax**

Press Releases

Dec 13, 2024 Corporate and finance

[Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First \\$50 Million Milestone](#)

## **Pfizer**

Recent Press Releases - No new digest announcements identified.

## **R-Pharm**

<https://rpharm-us.com/index.php>  
*[No news or media page identified]*

## **Sanofi Pasteur**

*Press Releases*

December 11, 2024

### **[Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US](#)**

*Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines*

- Pneumococcal disease remains a major global health challenge despite the availability of current vaccines
- This 21-valent pneumococcal conjugate vaccine (PCV21) is the first pneumococcal conjugate vaccine candidate with more than 20 serotypes to enter phase 3 in infants & toddlers

## **Serum Institute**

*News & Announcements*

Thursday, Dec 19, 2024

### **[Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India](#)**

Monday, Dec 16, 2024

### **[Bavarian Nordic Enters License and Manufacturing Agreement for its Mpox Vaccine with Serum Institute of India](#)**

## **Sinopharm/WIBPBIBP**

*News* - No new digest announcements identified

## **Sinovac**

*Press Releases*

2024/12/16

### **[SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease \(HFMD\)](#)**

The first phase III clinical trial on a multivalent HFMD vaccine in the world

## **SK Biosciences**

*Press Releases*

### **[SK bioscience and Sanofi Expand Partnership to Develop Next-Generation Pneumococcal Conjugate Vaccines](#)**

-Both companies sign an expanded agreement to develop next-generation pneumococcal vaccines.-  
2024.12.23

## **Takeda**

*Newsroom* - No new digest announcements identified.

## **Valneva**

*Press Releases*

December 19, 2024

### **[Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India](#)**

## **Vector State Research Centre of Virology and Biotechnology**

Home - [Website not responding [404 error]]

## **WestVac Biopharma**

Media - Website not responding at inquiry.

## **Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

.....  
.....

## **Contents [click to move among sections]**

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....  
.....

## **Journal Watch**

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

## **AJOB Empirical Bioethics**

Volume 15, 2023 Issue 4

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

## **AMA Journal of Ethics**

Volume 27, Number 1: E1-65 Jan 2025

<https://journalofethics.ama-assn.org/issue/epidemiology-and-clinical-practice>

### ***Epidemiology and Clinical Practice***

Epidemiological research guides health service delivery by informing and transforming clinical guidelines. Reciprocally, how clinicians document information from patients or their loved ones also determines the quality of data epidemiologists use in research. Additionally, some patients' health needs and some communities' health interests are not well captured in observational studies and clinical trials, especially when patient-subjects are lost to follow-up. Attrition of patient-subjects who are uninsured, underinsured, experience transportation or food insecurity, work multiple jobs, or live with complex chronic illnesses or disabilities, for example, creates data capture gaps, which can result in an evidence base that is incomplete and clinical guidelines that are inapt, inequitable, or simply do not apply to a full range of patients. This theme issue investigates these and other complexities of epidemiological data sourcing and the ethics of practice guideline formation.

## **American Journal of Human Genetics**

Jan 02, 2025 Volume 112 Issue 1 p1-198

<https://www.cell.com/ajhg/current>

### **This month in *The Journal***

Alyson B. Barnes, Kylee L. Spencer, Sara B. Cullinan

Loss-of-function variants are typically considered in terms of gene-specific, pathway-dependent effects. An altered protein is produced, affecting the protein-specific pathway or a related phenotype. However, characterizing the gene-specific, pathway-dependent effects alone does not always explain the phenotypic variability observed between individuals with the same mutation or predict disease trajectory. In this issue, Shovlin and Aldred present a parallel paradigm for loss-of-function variants based on proteostasis, the process of maintaining a healthy balance of proteins within a cell.

## **American Journal of Infection Control**

January 2025 Volume 53 Issue 1p1-174

<http://www.ajicjournal.org/current>

### ***Major Articles***

#### **National trends and disparities in herpes zoster vaccination among US older adults with chronic obstructive pulmonary disease, 2008 to 2022**

Chun-Tse Hung, et al.

Published online: August 15, 2024

p75-81

#### **Changes in the mumps vaccine coverage and incidence of mumps before and after the public subsidization program: A descriptive study using a population-based database in Japan**

So Sato, et al.

Published online: September 15, 2024

p82-86 Open Access

#### **COVID-19 vaccine uptake inequality among older adults: A multidimensional demographic analysis**

Seyed M. Karimi, et al.

Published online: September 12, 2024

p115-125

## **American Journal of Preventive Medicine**

January 2025 Volume 68 Issue 1 p1-216

<https://www.ajpmonline.org/current>

### ***Research Articles***

#### **Cost-Effectiveness of Varicella Vaccination for 1–4-Year-Olds in Shanghai, China**

Baichu Guan, et al.

Published online: August 16, 2024

p12-22

### ***Review Articles***

#### **Disease Intervention Specialist-Delivered Interventions and Other Partner Services for HIV and Sexually Transmitted Infections: A Systematic Review**

Erika G. Martin, et al.



Published online: August 12, 2024  
p182-203  
Open Access

### **American Journal of Public Health**

January 2025 115(1)

<http://ajph.aphapublications.org/toc/ajph/current>

#### ***Displacements to Escape Natural Disasters In The United States***

The January issue of *AJPH* focuses on the increasing prevalence of natural disaster-induced displacements within the United States. Featured articles explore disparities in the impact of these displacements and examine their prevalence and correlates. Other articles in this issue address naloxone distribution programs, urban reforestation efforts in Manhattan, the role of health monitoring data in relation to immigration and citizenship, and the use of long-acting reversible contraception.

### **American Journal of Tropical Medicine and Hygiene**

Volume 111 (2024): Issue 6 (Dec 2024)

<https://www.ajtmh.org/view/journals/tpmd/111/4/tpmd.111.issue-6.xml>

*Articles*

[Reviewed earlier]

### **Annals of Internal Medicine**

December 2024 Volume 177, Issue 12

<https://www.acpjournals.org/toc/aim/current>

[New issue; No digest content identified]

### **Artificial Intelligence – An International Journal**

Volume 337 December 2024

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/337/suppl/C>

[Reviewed earlier]

### **BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 03 Jan 2025)

[No new digest content identified]

### **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 03 Jan 2025)

#### **Effective coverage of maternal and neonatal healthcare services in low-and middle-income countries: a scoping review**

*There is no consistent operationalization of effective coverage (EC) across studies. Therefore, this scoping review synthesized evidence on the definitions and measurement approaches, outcomes reported, and th...*

Authors: Ayelign Mengesha Kassie, Elizabeth Eakin, Aklilu Endalamaw, Anteneh Zewdie, Eskinder Wolka and Yibeltal Assefa

Citation: *BMC Health Services Research* 2024 24:1601

Content type: Research Published on: 18 December 2024

### **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 03 Jan 2025)

#### **[Socioeconomic and geographical inequalities in polio immunisation coverage among two-year-olds in Sierra Leone, 2008–2019](#)**

*Polio, a debilitating and potentially life-threatening disease, continues to pose a risk to young children globally. While vaccination offers a powerful shield, its reach is not always equal. This study explo...*

Authors: Augustus Osborne, Umaru Sesay, Alieu Tommy, Alpha Umaru Bai-Sesay, Camilla Bangura and Jia B. Kangbai

Citation: *BMC Infectious Diseases* 2024 24:1461

Content type: Research Published on: 24 December 2024

### **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 03 Jan 2025)

[No new digest content identified]

### **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 03 Jan 2025)

[No new digest content identified]

### **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 03 Jan 2025)

[No new digest content identified]

### **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 03 Jan 2025)

#### **[What makes an epidemic a disaster: the future of epidemics within the EM-DAT International Disaster Database](#)**

*Reporting on and monitoring epidemics is a public health priority. Several initiatives and platforms provide epidemiological data, such as the EM-DAT International Disaster Database, which has 1525 epidemics and their impact reported since 1900, including 892 epidemics between 2000 and 2023. However, EM-DAT has inconsistent coverage and deficiencies regarding the systematic monitoring of epidemics data due to the lack of a standardized methodology to define what will be included under an epidemic disaster.*

Authors: Margo Tonnelier, Damien Delforge, Regina Below, Juan Armando Torres Munguía, Claude Saegerman, Valentin Wathélet, Joris A. F. van Loenhout and Niko Speybroeck

Citation: *BMC Public Health* 2025 25:21

Content type: Research Published on: 3 January 2025

#### **[Willingness to receive COVID-19 vaccine and associated factors among teachers in Dambi Dollo, Ethiopia: a cross-sectional study](#)**

*Teachers play important roles in influencing vaccine uptake decisions and should serve as examples for their students by willingly getting vaccinated. Given the low vaccination rates in this area, it is crucial...*

Authors: Desalegn Shiferaw, Chara Melaku, Lemessa Assefa and Tadele Kinati

Citation: BMC Public Health 2025 25:13

Content type: Research Published on: 2 January 2025

### **Confidence in the efficacy of routine vaccines after the COVID-19 pandemic: a cross-sectional web-based study**

There is limited data that assessed the changes in public confidence in routine childhood and adult vaccines after Corona Virus Disease-2019 (COVID-19) pandemic. We, therefore, assessed these changes and the r...

Authors: Areej M. Zubaid, Maha T. Alhamdi, Noor I. Al-Harthi, Khulood M. Al-Harthi, Razan A. AlQarni, Yassmin M. Shebany, Ahmed Ibrahim Fathelrahman and Sayed F. Abdelwahab

Citation: BMC Public Health 2024 24:3608

Content type: Research Published on: 30 December 2024

### **Parental/guardians' satisfaction with vaccination service and its associated factors: a cross-sectional study from Eastern China**

*Vaccination is a simple and effective preventative measure against infections and diseases among populations, especially children. This study aimed to evaluate parental/guardians' satisfaction with vaccination...*

Authors: Guohua Qian, Jie Yang, Xiaofei Ding, Miao Xu, Qingqing Yue, Huanxi Shen and Hui Zuo

Citation: BMC Public Health 2024 24:3574

Content type: Research Published on: 23 December 2024

### **Mobilizing community engagement for crisis response: lessons learned from a COVID-19 mass vaccination clinic in Cobourg, Ontario, Canada**

*Communities have an important role to play in disaster and emergency planning and response. Yet community members are not typically engaged in official planning activities, including plans for mass immunization...*

Authors: Crystal Gaudet, Emily Field and Sayra Cristancho

Citation: BMC Public Health 2024 24:3544

Content type: Research Published on: 19 December 2024

### **Factors associated with COVID-19 vaccination rates in countries with different income levels: a panel analysis**

*Vaccines against coronavirus disease (COVID-19) are being developed and supplied at an unprecedented rate. However, disparities in income levels among countries has influenced the supply and vaccination rate. ...*

Authors: Jeong-Yeon Cho, Sun-Hong Kwon, Jong-Seop Lee, Jinhyung Lee, Jong-Hwan Lee, Yuna Chae and Eui-Kyung Lee

Citation: BMC Public Health 2024 24:3538

Content type: Research Published on: 19 December 2024

### **Prioritizing vaccine introduction to China's National Immunization Program: a multi-criteria decision analysis**

*To prioritize the introducing of new vaccines into China's National Immunization Program (NIP) among 10 candidate vaccines across four classes.*

Authors: Jianming Guo, Bin Zheng, Tingting Chen, Shuyan Guo, Maobai Liu and Siping Dong

Citation: BMC Public Health 2024 24:3458

Content type: Research Published on: 18 December 2024

**Factors associated with parental intentions to vaccinate 0-4-year-old children against COVID-19 in Canada: a cross-sectional study using the Childhood COVID-19 Immunization Coverage Survey (CCICS)**

*The objective of this study was to determine the factors associated with low or no parental intention to vaccinate children of 0-4-years in Canada with a COVID-19 vaccine through the 2022 Childhood COVID-19 Im...*

Authors: Israa Zareef, Anna-Maria Frescura, Saily Dave, Caren Uhlik, David Guan, Hussein Samhat, Marwa Ebrahim and Julie Laroche

Citation: BMC Public Health 2024 24:3456

**Factors associated with COVID-19 vaccine acceptance and hesitancy in children: a comprehensive survey**

*The COVID-19 pandemic has underscored the significance of immunizations, particularly among susceptible populations such as children. This study examines the factors that influence parents' decision to accept ...*

Authors: Saber Gharagozlou, Fatemeh Azizi, Elmira Hajiesmaeil Memar, Sara Memarian, Mahsa Soti Khiabani, Roya Mohammadi, Parisa Ashournia, Raha Zamani, Zahra Zamani and Mohammad Gharagozlou

Citation: BMC Public Health 2024 24:3455

Content type: Research Published on: 18 December 2024

**Behaviors and willingness to support HPV vaccination for women: a cross-sectional study of young adult men in China**

*Men's involvement in and support for women's decision-making concerning human papillomavirus (HPV) vaccination is crucial. However, the support provided by men to promote HPV vaccination among women, as a cruc...*

Authors: Weiyi Wang

Citation: BMC Public Health 2024 24:3429

Content type: Research Published on: 18 December 2024

**BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 03 Jan 2025)

[No new digest content identified]

**BMJ Evidence-Based Medicine**

December 2024 - Volume 29 - 6

<https://ebm.bmj.com/content/29/6>

[Reviewed earlier]

**BMJ Global Health**

December 2024 - Volume 9 - 12

<https://gh.bmj.com/content/9/12>

[Reviewed earlier]

**Bulletin of the World Health Organization**

2024 Dec 1; 102(12)

<https://www.who.int/publications/journals/bulletin/>

### **In this month's Bulletin**

This month's theme issue on sexual health is introduced in an editorial by Manjulaa Narasimhan and Pascale Allotey (842). In related editorials, Sagri Singh et al. (843) advocate for improved sexual health and well-being and Nicaise Ndembi et al. (844) explain how mpox poses a new threat. Etienne V Langlois et al. (845) present a critical pathway for the reduction of maternal newborn and child mortality.

Gary Humphrey (848–849) reports on efforts to communicate effectively about mpox transmission while avoiding stigmatization. Haven Ley talks to Humphreys (850–851) about Pivotal Ventures, established to further social progress and address women's sexual health and reproductive rights.

### **Cell**

Dec 26, 2024 Volume 187 Issue 26 p7351-7656

<https://www.cell.com/cell/current>

[New issue; No digest content identified]

### **Child Care, Health and Development**

Volume 51, Issue 1 January 2025

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

### **Clinical Pharmacology & Therapeutics**

Volume 116, Issue 6 Pages: 1353-1645 December 2024

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

***Therapeutic Innovations in Rare and Orphan Diseases***

[Reviewed earlier]

### **Clinical Therapeutics**

December 2024 Volume 46 Issue 12 p941-1092

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

### **Clinical Trials**

Volume 21 Issue 6, December 2024

<https://journals.sagepub.com/toc/ctja/21/6>

[Reviewed earlier]

### **Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 03 Jan 2025]

[No new digest content identified]

### **Contemporary Clinical Trials**

Volume 147 December 2024

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/147/suppl/C>

[Reviewed earlier]

## **The CRISPR Journal**

Volume 7, Issue 6 / December 2024

<https://www.liebertpub.com/toc/crispr/7/6>

Review Articles

### **Early Detection of Wildlife Disease Pathogens Using CRISPR-Cas System Methods**

Adam A. Pérez, Guelaquetza Vazquez-Meves, and Margaret E. Hunter

Pages:327–342

Published Online:31 October 2024

#### ***Abstract***

Wildlife diseases are a considerable threat to human health, conservation, and the economy. Surveillance is a critical component to mitigate the impact of animal diseases in these sectors. To monitor human diseases, CRISPR-Cas (clustered regularly interspaced short palindromic repeats-CRISPR-associated protein) biosensors have proven instrumental as diagnostic tools capable of detecting unique DNA and RNA sequences related to their associated pathogens. However, despite the significant advances in the general development of CRISPR-Cas biosensors, their use to support wildlife disease management is lagging. In some cases, wildlife diseases of concern could be rapidly surveyed using these tools with minimal technical, operational, or cost requirements to end users. This review explores the potential to further leverage this technology to advance wildlife disease monitoring and highlights how concerted standardization of protocols can help to ensure data reliability.

## **Current Genetic Medicine Reports**

Volume 11, Issue 3-4 December 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-3>

[Reviewed earlier]

## **Current Medical Research and Opinion**

Volume 40, Issue 12 2024

<https://www.tandfonline.com/toc/icmo20/current>

[New issue; No digest content identified]

## **Current Opinion in Infectious Diseases**

December 2024 - Volume 37 - Issue 6

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

## **Current Protocols in Human Genetics**

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 03 Jan 2025]

[No new digest content identified]

## **Developing World Bioethics**

Volume 24, Issue 4 Pages: 263-342 December 2024

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

**Development in Practice**

Volume 34, Issue 6, 2024

<https://www.tandfonline.com/toc/cdip20/34/6>

[Reviewed earlier]

**Development Policy Review**

Volume 43, Issue 1 January 2025

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

**Disaster Medicine and Public Health Preparedness**

Volume 18 - 2024

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

**Disasters**

Volume 49, Issue 1 January 2025

<https://onlinelibrary.wiley.com/toc/14677717/2025/49/1>

*ORIGINAL ARTICLE*

[\*\*Connecting efficiency and responsiveness in China: public sentiments and stakeholder perspectives towards COVID-19 crisis governance\*\*](#)

Ronghui Yang, Bart Penders, Klasien Horstman

e12652

First Published: 09 August 2024

**EMBO Reports**

Volume 25 Issue 12 6 December 2024

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

**Emerging Infectious Diseases**

Volume 30, Number 11—November 2024

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

**Epidemics**

Volume 49 December 2024

<https://www.sciencedirect.com/journal/epidemics/vol/49/suppl/C>

[Reviewed earlier]

**Epidemiology and Infection**

Volume 152 - 2024

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>



[Reviewed earlier]

### **Ethics & Human Research**

Volume 46, Issue 6 Pages: 1-35 November–December 2024

<https://onlinelibrary.wiley.com/toc/25782363/current>

***Data monitoring committee insights / Ethics reviews and AI tools***

[Reviewed earlier]

### **Ethics & International Affairs**

Volume 38 - Issue 2 - Summer 2024

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

### **Ethics, Medicine and Public Health**

Volume 32 2024

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc>

[Reviewed earlier]

### **The European Journal of Public Health**

Volume 34, Issue 5, October 2024

<https://academic.oup.com/eurpub/issue/34/5>

[Reviewed earlier]

### **Expert Review of Vaccines**

Vol 23 (1) 2023

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

### **Foreign Affairs**

November/December 2024 Volume 103, Number 6

<https://www.foreignaffairs.com/issues/2023/103/6>

[Reviewed earlier]

### **Forum for Development Studies**

Volume 51, 2024 - Issue 3

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

### **Frontiers in Medicine**

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1237>

[Accessed 03 Jan 2025]

[No new digest content identified]

## **Genetics in Medicines**

Volume 26, Issue 12 December 2024

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/12>

[Reviewed earlier]

## **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 03 Jan 2025]

[No new digest content identified]

## **Global Health Action**

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

## **Global Health: Science and Practice (GHSP)**

Vol. 12, No. 6 December 20, 2024

<http://www.ghspjournal.org/content/current>

*SHORT REPORTS*

Open Access

### **[Accelerating Progress in Women's Sexual and Reproductive Health and Rights Decision-Making: Trends in 32 Low- and Middle-Income Countries and Future Perspectives](#)**

Mengjia Liang, Lindsay Katz, Emilie Filmer-Wilson and Priscilla Idele

Global Health: Science and Practice December 2024, 12(6):e2400228; <https://doi.org/10.9745/GHSP-D-24-00228>

This study highlights significant country and subnational variations in the progress of achieving universal sexual and reproductive health and reproductive rights, demonstrating the urgent need for targeted, culturally informed interventions to empower women globally and close persistent gaps in reproductive rights and bodily autonomy.

## **Global Legal Monitor & Legal Reports – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>

[https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date\\_desc](https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc)

[Accessed 03 Jan 2025]

[No new digest content identified]

## **Global Public Health**

Volume 19, Issue 1 (2024)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

## **Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 03 Jan 2025]

## **China's position and competitiveness in the global antibiotic value chain: implications for global health**

Antibiotics are a key commodity for global health, and inadequate access is a major contributor to global mortality. COVID-19 has refocused attention on global pharmaceutical value chains and the need for sust...

Authors: Yang Yang, Lewis Husain and Yangmu Huang

Citation: *Globalization and Health* 2024 20:87

Content type: Research Published on: 18 December 2024

## **Health and Human Rights**

Volume 26, Issue 2, December 2024

<https://www.hhrjournal.org/volume-26-issue-2-december-2024/>

***Special Section: Distress Migration and the Right to Health***

[Reviewed earlier]

## **Health Economics, Policy and Law**

Volume 19 - Issue 3 - July 2024

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

## **Health Policy and Planning**

Volume 39, Issue 10, December 2024

<https://academic.oup.com/heapol/issue/39/10>

[Reviewed earlier]

## **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 03 Jan 2025]

[No new digest content identified]

## **Human Gene Therapy**

Volume 35, Issue 23-24 / December 2024

<https://www.liebertpub.com/toc/hum/35/21-24>

[Reviewed earlier]

## **Humanitarian Practice Network**

<https://odihpn.org/>

*Featured Publications*

[No new digest content identified]

## **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 20 Issue 1, 2024

<https://www.tandfonline.com/toc/khvi20/20/1?nav=tocList>

*Selected Content*

[Reviewed earlier]

## **Immunity**

Dec 10, 2024 Volume 57 Issue 1 2p2705-2958

<https://www.cell.com/immunity/current>

[Reviewed earlier]

## **Infectious Agents and Cancer**

<http://www.infectagentscancer.com/>

[Accessed 03 Jan 2025]

[No new digest content identified]

## **Infectious Diseases of Poverty**

<http://www.idpjournal.com/content>

[Accessed 03 Jan 2025]

[No new digest content identified]

## **International Health**

Volume 17, Issue 1, January 2025

<https://academic.oup.com/inthealth/issue/17/1>

*Original Articles*

**[Deployment of vaccine cold chain equipment in resource-limited settings: lessons from the Gavi Cold Chain Optimization Platform in Cameroon](#)**

Jude Nkwain and others

**[Covid-19 vaccination coverage and associated factors among older hypertensive patients in Hangzhou, China](#)**

Shijun Liu and others

## **International Human Rights Law Review**

Volume 13 (2024): Issue 1 (Jun 2024):

<https://brill.com/view/journals/hrlr/13/1/hrlr.13.issue-1.xml>

***Special Issue on Inter-State Communications***

*Table of Contents*

[Reviewed earlier]

## **International Journal of Community Medicine and Public Health**

Vol. 12 No. 1 (2025): January 2025

<https://www.ijcmph.com/index.php/ijcmph/issue/view/120>

*Original Research Articles*

**[Knowledge, attitude and utilization of oral cholera vaccine in Bauchi Metropolis, Bauchi State, North-Eastern Nigeria](#)**

Aliyu M. Maigoro, Khadija U. Ibrahim, Usman S. Usman, Ibrahim A. Abdullahi, Ado Shehu

68-79

DOI: [10.18203/2394-6040.ijcmph20244002](https://doi.org/10.18203/2394-6040.ijcmph20244002)

*Review Articles*

## [\*\*Public health strategies to combat measles outbreaks in low-vaccination areas\*\*](#)

Sultan M. Alsharif, Amroo K. Noorelahi, Thamer M. Althagafi, Lama T. Alsayel, Lena H. Alfaraj, Raqda B. Alshamase, Ammar A. Hejji, Samia A. Alzhrani, Rayed Y. Arishi, Nainawa A. Alsuaileek, Danya W. Alfadl, Hanadi A. Abdulkarim  
499-503

DOI: [10.18203/2394-6040.ijcmph20244061](#)

## **International Journal of Epidemiology**

Volume 53, Issue 6, December 2024

<https://academic.oup.com/ije/issue/53/6>

[Reviewed earlier]

## **International Journal of Human Rights in Healthcare**

Volume 17 Issue 4 2024

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/4>

*Table of contents*

[Reviewed earlier]

## **JAMA**

<https://jamanetwork.com/journals/jama/currentissue>

**December 24/31, 2024, Vol 332, No. 24, Pages 2049-2158**

*JAMA Insights*

### [\*\*Dengue\*\*](#)

Laura E. Adams, DVM, MPH; Joshua M. Wong, MD; Gabriela Paz-Bailey, MD, PhD, MSc

JAMA. 2024;332(24):2109-2110. doi:10.1001/jama.2024.21094

This JAMA Insights explores several aspects of dengue virus infection, including epidemiology, diagnosis, and clinical management, following a global resurgence in both endemic and nonendemic regions.

**December 17, 2024, Vol 332, No. 23, Pages 1959-2046**

*Viewpoint*

### [\*\*Rare Disease Innovation at the FDA—Opportunities for Implementation\*\*](#)

Carolyn K. Shore, PhD; Tequam L. Worku, MPH; Jeffrey Kahn, PhD, MPH

JAMA. 2024;332(23):1973-1974. doi:10.1001/jama.2024.20358

This Viewpoint discusses new pathways for researchers to seek collaboration when conducting studies on treatments for rare diseases and conditions.

*Original Investigation*

### [\*\*Electronic Nudges to Increase Influenza Vaccination in Patients With Chronic DiseasesA Randomized Clinical Trial\*\*](#)

Niklas Dyrby Johansen, MD, PhD; Muthiah Vaduganathan, MD, MPH; Ankeet S. Bhatt, MD, MBA, ScM; et al.

JAMA. 2024;332(22):1900-1911. doi:10.1001/jama.2024.21060

This randomized clinical trial evaluates whether behaviorally informed electronically delivered letter-based nudges could increase influenza vaccination among adults with chronic diseases.

*AI in Medicine*

### [\*\*FDA Commissioner Robert Califf on Setting Guardrails for AI in Health Care\*\*](#)

Roy Perlis, MD, MSc; Jennifer Abbasi

free access has multimedia has audio

JAMA. 2024;332(23):1963-1966. doi:10.1001/jama.2024.24760

This Medical News article is an interview with FDA Commissioner Robert Califf, MD, about the agency's regulatory powers over artificial intelligence tools for use in health care and biomedicine.

### **JAMA Health Forum**

January 2025, Vol 6, No. 1

<https://jamanetwork.com/journals/jama-health-forum/issue>

*Research Letter*

#### **Expedited Approval of Urgently Needed Drugs in China**

Yuxuan Wei, MFin; Yichen Zhang, MSc; Huangqianyu Li, MPH; et al.

open access

*JAMA Health Forum*. 2025;6(1):e244750. doi:10.1001/jamahealthforum.2024.4750

This cross-sectional study evaluates the approval status and timeline and therapeutic value of urgently needed overseas drugs in China.

### **JAMA Pediatrics**

December 2024, Vol 178, No. 12, Pages 1237-1379

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[New issue; No digest content identified]

### **JB I Evidence Synthesis**

December 2024 - Volume 22 - Issue 12

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[New issue; No digest content identified]

### **Journal of Adolescent Health**

January 2025 Volume 76 Issue 1 p1-172

<https://www.jahonline.org/current>

[New issue; No digest content identified]

### **Journal of Artificial Intelligence Research**

Vol. 81 (2024)

<https://www.jair.org/index.php/jair>

*Contents*

[Reviewed earlier]

### **Journal of Community Health**

Volume 49, Issue 6 December 2024

<https://link.springer.com/journal/10900/volumes-and-issues/49-6>

[Reviewed earlier]

### **Journal of Current Medical Research and Opinion**

*...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.*

Vol. 7 No. 11 (2024)

<https://www.cmro.in/index.php/jcmro/issue/view/89>

[Reviewed earlier]

### **Journal of Development Economics**

Volume 172 January 2025

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/172/suppl/C>

[Reviewed earlier]

### **Journal of Empirical Research on Human Research Ethics**

Volume 19 Issue 4-5, October–December 2024

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

### **Journal of Epidemiology & Community Health**

November 2024 - Volume 78 - 11

<https://jech.bmj.com/content/78/11>

[Reviewed earlier]

### **Journal of Evidence-Based Medicine**

Volume 17, Issue 4 Pages: 689-873 December 2024

<https://onlinelibrary.wiley.com/toc/17565391/current>

***GUIDELINE***

**[Technical specification for developing a clinical practice guideline for the integration of traditional Chinese medicine and Western medicine](#)**

Jianxin Wang, Rui Sun, Fengwen Yang, Jianping Liu, Jiajie Yu, Yuanyuan Sun, Xuemin Gao, Boli Zhang, Junhua Zhang, Jinzhou Tian

Pages: 865-873

First Published: 17 October 2024

### **Journal of Global Ethics**

Volume 20, Issue 3 (2024)

<http://www.tandfonline.com/toc/rjge20/current>

***Special Issue: 20th Anniversary Forum***

[New issue; No digest content identified]

### **Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 35, Number 4, November 2024

<https://muse.jhu.edu/issue/53739>

*Table of Contents*

[Reviewed earlier]

### **Journal of Immigrant and Minority Health**

Volume 26, Issue 5 October 2024

<https://link.springer.com/journal/10903/volumes-and-issues/26-5>

[Reviewed earlier]

### **Journal of Immigrant & Refugee Studies**

Volume 22, 2024 \_ Issue 4

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

### **Journal of International Development**

Volume 36, Issue 8 Pages: 1-3156 November 2024

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

### **Journal of Medical Ethics**

January 2025 - Volume 51 - 1

<http://jme.bmj.com/content/current>

*Extended essay*

[\*\*Ethics of the fiduciary relationship between patient and physician: the case of informed consent\*\*](#) (23 December, 2022)

Sophie Ludewigs, Jonas Narchi, Lukas Kiefer, Eva C Winkler

### **Journal of Patient-Centered Research and Reviews**

Volume 11, Issue 3 (2024)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

### **The Journal of Pediatrics**

Volume 275 December 2024

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/275/suppl/C>

*European Paediatric Association*

*Editorial*

[\*\*The Role of Artificial Intelligence in Pediatrics from Treating Illnesses to Managing Children's Overall Well-Being\*\*](#)

Flavia Indrio, Massimo Pettoello-Mantovani, Ida Giardino, Elio Masciari

Article 114291

### **Journal of Pharmaceutical Policy and Practice**

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/jppp20/17/1>

[Reviewed earlier]

### **Journal of Public Health Management & Practice**

January/February 2025 - Volume 31 - Issue 1



<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

*Commentary*

**Balancing Parental Rights and Public Health: The Challenge of Childhood Vaccination in a Changing Landscape**

Yang, Y. Tony; DeRoo, Sarah Schaffer

**Journal of Public Health Policy**

Volume 45, issue 4, December 2024

<https://link.springer.com/journal/41271/volumes-and-issues/45-4>

[Reviewed earlier]

**Journal of the Royal Society – Interface**

December 2024 Volume 21 Issue 221

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

**Journal of Travel Medicine**

Volume 31, Issue 8, December 2024

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

**Journal of Virology**

Volume 98 • Number 11 • November 2024

<http://jvi.asm.org/content/current>

[Reviewed earlier]

**The Lancet**

<https://www.thelancet.com/journals/lancet/issue/current>

**Jan 04, 2025 Volume 405 Number 10472 p1-96**

*Editorial*

**Can we turn the tide on NCDs in 2025?**

The Lancet

*Review*

**Concurrent outbreaks of mpox in Africa—an update**

Camila G Beiras, Emile Malembi, Roser Escrig-Sarreta, Steve Ahuka, et al.

*Summary*

In this Review, we examine the concurrent outbreaks of mpox in Africa, focusing on clade 1a, the newly emerged clade 1b, and clade 2b lineage A, and how they differ from the 2022 global outbreak caused by clade 2b lineage B.1. Historically, clades 1a and 2a have caused sporadic, small outbreaks in central and west Africa, respectively, primarily through zoonotic transmission. Clade 2b first caused an outbreak in Nigeria in 2017, and later spread globally via sexual contact in 2022. In August, 2024, WHO declared a global health emergency due to the newly identified clade 1b outbreak in eastern Democratic Republic of the Congo. This outbreak has now expanded to several other countries and is spreading through direct and sexual contact in urban centres and refugee camps. Clades, route of exposure, infectious dose, and host immune response are the main factors influencing clinical presentation of mpox. For clades 1a and 2a, zoonotic transmission plays an important role, whereas for

clades 1b and 2b, the spread occurs through sustained human-to-human transmission without zoonotic exposure. For both clades 1a and 2a, lesions have a generalised centrifugal distribution, whereas for clade 2b they are mainly localised to the anogenital area. For clade 1b, data are still emerging, but current cases show a mix of localised lesions and centrifugal distribution. The severity of the disease is higher for clade 1a (case fatality rate up to 12%) compared with other clades (case fatality rates 0–3·6%). Diagnostic challenges include false negative results for clade 1b with existing PCR assays and poor testing access in remote areas. Tecovirimat, the primary antiviral during the 2022 outbreak, has shown reduced effectiveness against clade 1a in preliminary study results, whereas its efficacy against other clades is still under investigation. The modified vaccinia Ankara–Bavarian Nordic vaccine has been shown to be up to 90% effective against clade 2b after two doses and is safe for children, although its effectiveness drops to 20% when used as post-exposure prophylaxis. Given the evolving nature of the monkeypox virus, ongoing research and strong public health responses are key to managing potential future outbreaks.

***Dec 21, 2024 Volume 404 Number 10471 p2487-2620***

*Articles*

**[Global, regional, and national progress towards the 2030 global nutrition targets and forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021](#)**

Global Nutrition Target Collaborators

*Open Access*

*Background*

The six global nutrition targets (GNTs) related to low birthweight, exclusive breastfeeding, child growth (ie, wasting, stunting, and overweight), and anaemia among females of reproductive age were chosen by the World Health Assembly in 2012 as key indicators of maternal and child health, but there has yet to be a comprehensive report on progress for the period 2012 to 2021. We aimed to evaluate levels, trends, and observed-to-expected progress in prevalence and attributable burden from 2012 to 2021, with prevalence projections to 2050, in 204 countries and territories.

### **The Lancet Child & Adolescent Health**

Dec 2024 Volume 8 Number 12 p843-932, e17

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

### **Lancet Digital Health**

Dec 2024 Volume 6 Number 12 e879-e943

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

### **Lancet Global Health**

Dec 2024 Volume 12 Number 12 e1910-e2079

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

### **Lancet Infectious Diseases**

Dec 2024 Volume 24 Number 12 p1287-1402, e725-e794

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

### **Lancet Public Health**

Dec 2024 Volume 9 Number 12 e995-e1141

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

### **Lancet Respiratory Medicine**

Dec 2024 Volume 12 Number 12 p933-1006, e75-e80

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

### **Maternal and Child Health Journal**

Volume 28, Issue 12 December 2024

<https://link.springer.com/journal/10995/volumes-and-issues/28-12>

*Articles*

#### **[Association Between a Mother's Cervical Cancer Screening and Child's Human Papillomavirus \(HPV\) Vaccination Status](#)**

Anna Bloom, Rachel Springer, Jennifer DeVoe

OriginalPaper 08 October 2024 Pages: 2137 - 2146

### **Medical Decision Making (MDM)**

Volume 45 Issue 1, January 2025

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

### **The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 102, Issue 4 Pages: 823-1031 December 2024

<https://onlinelibrary.wiley.com/toc/14680009/current>

[New issue; No digest content identified]

### **Molecular Therapy**

Dec 04, 2024 Volume 32 Issue 12 p4163-4534

<https://www.cell.com/molecular-therapy/current>

[Reviewed earlier]

### **Nature**

<https://www.nature.com/nature/volumes/637/issues/8044>

#### ***Volume 637 Issue 8044, 2 January 2025***

*Editorial* 30 Dec 2024

#### **[2025 must be the year when the rules of global finance are reformed](#)**

The current international financial architecture is a key reason that the UN Sustainable Development Goals are failing. A landmark conference in Spain must make progress in reforming it.

Article Open Access 01 Jan 2025

#### **[High-resolution genomic history of early medieval Europe](#)**

Twigstats, a method for ancestry reconstruction, provides high-resolution genetic histories and movement patterns of people living in Europe during the first millennium ce.  
Leo Speidel, Marina Silva, Pontus Skoglund

**Volume 636 Issue 8043, 19 December 2024**

*Editorial* 17 Dec 2024

**[Good COPs, bad COPs: science struggles in a year of environmental summits](#)**

The system meant to ensure that international agreements are informed by a consensus of rigorous research is under severe stress.

**Nature Biotechnology**

Volume 42 Issue 12, December 2024

<https://www.nature.com/nbt/volumes/42/issues/12>

[Reviewed earlier]

**Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 03 Jan 2025)

[Reviewed earlier]

**Nature Genetics**

Volume 56 Issue 12, December 2024

<https://www.nature.com/ng/volumes/56/issues/12>

[Reviewed earlier]

**Nature Human Behaviour**

Volume 8 Issue 11, November 2024

<https://www.nature.com/nathumbehav/volumes/8/issues/11>

[Reviewed earlier]

**Nature Medicine**

Volume 30 Issue 12, December 2024

<https://www.nature.com/nm/volumes/30/issues/12>

[Reviewed earlier]

**Nature Reviews Drug Discovery**

Volume 23 Issue 12, December 2024

<https://www.nature.com/nrd/volumes/23/issues/12>

[Reviewed earlier]

**Nature Reviews Genetics**

Volume 25 Issue 12, December 2024

<https://www.nature.com/nrg/volumes/25/issues/12>

[Reviewed earlier]

## **Nature Reviews Immunology**

Volume 24 Issue 12, December 2024

<https://www.nature.com/nri/volumes/24/issues/12>

[Reviewed earlier]

## **New England Journal of Medicine**

<https://www.nejm.org/toc/nejm/medical-journal>

**Volume 392 No. 1 January 2, 2025**

*Review Article*

### **Cervical Cancer**

Author: Krishnansu S. Tewari, M.D.

Published January 1, 2025

*Abstract*

Accounting for approximately 350,000 deaths annually worldwide, cervical cancer is preventable with HPV vaccination and screening. Newer chemotherapy, radiotherapy, and immunotherapy techniques have improved survival.

*Medicine and Society*

### **Long-Acting HIV Medicines and the Pandemic Inequality Cycle — Rethinking Access**

W. Byanyima, L.-G. Bekker, and M.M. Kavanagh

**Volume 391 No. 24 December 19, 2024**

*Original Articles*

### **Ebola Outbreak Response in the DRC with rVSV-ZEBOV-GP Ring Vaccination**

J.-J. Muyembe and Others

## **Nature Biotechnology**

Volume 42 Issue 12, December 2024

<https://www.nature.com/nbt/volumes/42/issues/12>

[Reviewed earlier]

## **Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 03 Jan 2025)

[Reviewed earlier]

## **Nature Genetics**

Volume 56 Issue 12, December 2024

<https://www.nature.com/ng/volumes/56/issues/12>

[Reviewed earlier]

## **Nature Human Behaviour**

Volume 8 Issue 11, November 2024

<https://www.nature.com/nathumbehav/volumes/8/issues/11>

[Reviewed earlier]

## **Nature Medicine**

Volume 30 Issue 12, December 2024

<https://www.nature.com/nm/volumes/30/issues/12>

[Reviewed earlier]

## **Nature Reviews Drug Discovery**

Volume 23 Issue 12, December 2024

<https://www.nature.com/nrd/volumes/23/issues/12>

[Reviewed earlier]

## **Nature Reviews Genetics**

Volume 25 Issue 12, December 2024

<https://www.nature.com/nrg/volumes/25/issues/12>

[Reviewed earlier]

## **Nature Reviews Immunology**

Volume 24 Issue 12, December 2024

<https://www.nature.com/nri/volumes/24/issues/12>

[Reviewed earlier]

## **New England Journal of Medicine**

<https://www.nejm.org/toc/nejm/medical-journal>

**Volume 392 No. 1 January 2, 2025**

*Review Article*

### **[Cervical Cancer](#)**

Author: Krishnansu S. Tewari, M.D.

Published January 1, 2025

*Medicine and Society*

### **[Long-Acting HIV Medicines and the Pandemic Inequality Cycle — Rethinking Access](#)**

W. Byanyima, L.-G. Bekker, and M.M. Kavanagh

**Volume 391 No. 24 December 19, 2024**

*Original Articles*

### **[Ebola Outbreak Response in the DRC with rVSV-ZEBOV-GP Ring Vaccination](#)**

J.-J. Muyembe and Others

## **NEJM Evidence**

Volume 3 No. 12 December 2024

<https://evidence.nejm.org/toc/evid/current>

*NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.*

[Reviewed earlier]

## **njp Vaccines**

<https://www.nature.com/npjvaccines/>  
[Accessed 03 Jan 2025]  
[No new digest content identified]

## **Pediatrics**

Volume 155, Issue 1 1 January 2025

<https://publications.aap.org/pediatrics/issue/155/1>

*Articles*

### **[Risk of Transmission of Vaccine-Strain Rotavirus in a Neonatal Intensive Care Unit That Routinely Vaccinates](#)**

Morgan A. Zalot, MPH; Margaret M. Cortese, MD; Kevin P. O'Callaghan, MBBCh; Mary C. Casey-Moore, PhD; Nathan L'Etoile, MD ...

*Commentaries*

### **[Rotavirus Vaccination in the NICU: It's Time to Turn Opportunity Into Action](#)**

Thomas J. Sandora, MD, MPH

## **PharmacoEconomics**

Volume 42, Issue 12 December 2024

<https://link.springer.com/journal/40273/volumes-and-issues/42-12>

[Reviewed earlier]

## **PLoS Biology**

<https://journals.plos.org/plosbiology/>

(Accessed 03 Jan 2025)

[No new digest content identified]

## **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 03 Jan 2025)

[No new digest content identified]

## **PLoS Global Public Health**

[https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\\_NEWEST\\_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSglobalPublicHealth&q=&resultsPerPage=60](https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSglobalPublicHealth&q=&resultsPerPage=60)

(Accessed 03 Jan 2025)

### **[ASEAN's response to mpox: Advancing regional and inter-regional cooperation to manage public health emergencies](#)**

Afifah Rahman-Shepherd, Ahmed Razavi, Ifedayo Adetifa, Ngozi Erundu, Soawapak Hinjoy, Zheng Jie Marc Ho, Irvin Miranda, Ebere Okereke, Oyeronke Oyebanji, Justin Wong, Ferdinal Fernando

Opinion | published 02 Jan 2025 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0003985>

### **[How have Ontario Public Health units engaged with faith-based organizations to build confidence in COVID-19 vaccines among ethno-racial communities](#)**

Kadidiatou Kadio, Melodie Yunju Song, Anna Karbasi, Denessia Blake-Hepburn, Shaza A. Fadel, Sara Allin, Anushka Ataullahjan, Erica Di Ruggiero  
Research Article | published 31 Dec 2024 PLOS Global Public Health  
<https://doi.org/10.1371/journal.pgph.0003924>

**[State and territory immunization program activities and their association with human papillomavirus vaccine initiation in the United States of America: A multilevel approach](#)**

Vivian Colón-López, Francisco J. Muñoz-Torres, Erika Escabí Wojna, Idamaris Vega Jimenez, Olga L. Díaz Miranda, Diana T. Medina-Laabes, Katelyn Wells, Ana P. Ortiz, Pamela C. Hull, Erick Suárez

Research Article | published 31 Dec 2024 PLOS Global Public Health  
<https://doi.org/10.1371/journal.pgph.0002852>

**[Understanding human papillomavirus vaccine response and efficacy in people living with HIV: A systematic mixed studies review and meta-analysis](#)**

Alvine M. Akumbom, Alanna J. Bergman, Howard Strickler, Chakra Budhathoki, Manka Nkimben, Raeven Grant, Nancy R. Reynolds, Kawsar R. Talaat

Research Article | published 20 Dec 2024 PLOS Global Public Health  
<https://doi.org/10.1371/journal.pgph.0003931>

**[“The COVID-19 pandemic in BRICS: Milestones, interventions, and molecular epidemiology”](#)**

Stephanie van Wyk, Monika Moir, Anindita Banerjee, Georgii A. Bazykin, Nidhan K. Biswas, Nikita Sitharam, Saumitra Das, Wentai Ma, Arindam Maitra, Anup Mazumder, Wasim Abdool Karim, Alessandra Pavan Lamarca, Mingkun Li, Elena Nabieva, Houriiyah Tegally, James Emmanuel San, Ana Tereza R. Vasconcelos, Joicymara S. Xavier, Eduan Wilkinson, Tulio de Oliveira

Research Article | published 20 Dec 2024 PLOS Global Public Health  
<https://doi.org/10.1371/journal.pgph.0003023>

**PLoS Medicine**

<https://journals.plos.org/plosmedicine/>

(Accessed 03 Jan 2025)

**[Protecting the most vulnerable: The urgent need to include HIV-exposed children in malaria chemoprevention strategies](#)**

Raquel González, Tacilta Nhampossa, Antía Figueroa-Romero, André-Marie Tchouatieu, Christine Manyando, Clara Menendez

Policy Forum | published 10 Dec 2024 PLOS Medicine  
<https://doi.org/10.1371/journal.pmed.1004498>

**PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 03 Jan 2025)

**[Efficacy of vaccines based on chimeric or multiepitope antigens for protection against visceral leishmaniasis: A systematic review](#)**

Karine Ferreira Lopes, Mariana Lourenço Freire, Silvane Maria Fonseca Murta, Edward Oliveira



Research Article | published 31 Dec 2024 PLOS Neglected Tropical Diseases  
<https://doi.org/10.1371/journal.pntd.0012757>

### **PLOS One**

<http://www.plosone.org/>

[Accessed 03 Jan 2025]

[No new digest content identified]

### **PLOS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 03 Jan 2025]

[No new digest content identified]

### **PNAS - Proceedings of the National Academy of Sciences of the United States**

December 17, 2024 | vol. 121 | no. 51

<https://www.pnas.org/toc/pnas/121/51>

[New issue; No digest content identified]

### **PNAS Nexus**

Volume 3, Issue 11, November 2024

<https://academic.oup.com/pnasnexus/issue/3/11>

[Reviewed earlier]

### **Prehospital & Disaster Medicine**

Volume 39 - Issue 3 - June 2024

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

### **Preventive Medicine**

Volume 189 December 2024

<https://www.sciencedirect.com/journal/preventive-medicine/vol/189/suppl/C>

[Reviewed earlier]

### **Proceedings of the Royal Society B**

December 2024 Volume 291 Issue 2036

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

### **Public Health**

Volume 237 Pages 1-466 (December 2024)

<https://www.sciencedirect.com/journal/public-health/vol/237/suppl/C>

[Reviewed earlier]

### **Public Health Ethics**

Volume 17, Issue 3, November 2024

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

### **Public Health Genomics**

2024, Vol. 27, No. 1

<https://karger.com/phg/issue/27/1>

[Reviewed earlier]

### **Public Health Reports**

Volume 139 Issue 6, November/December 2024

<https://journals.sagepub.com/toc/phrg/139/6>

[Reviewed earlier]

### **Qualitative Health Research**

Volume 35 Issue 1, January 2025

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

### **Research Ethics**

Volume 21 Issue 1, January 2025

<http://journals.sagepub.com/toc/reab/current>

*Review Article*

[\*\*A rapid review of the benefits and challenges of dynamic consent\*\*](#)

Winnie Lay, et al.

### **Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 03 Jan 2025]

[No new digest content identified]

### **Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

*Latest Articles*

19 Dec 2024

[\*\*Successes and challenges in achieving and sustaining the elimination of measles, rubella, and congenital rubella syndrome in the Americas, 2013-2023\*\*](#)

Special report | Spanish

19 Dec 2024

[\*\*Restructuring of the COVID-19 Vaccine Safety Committee 2020-2023 in Mexico\*\*](#)

Special report | Spanish

19 Dec 2024

**[Impact of the new intervention model to increase vaccination coverage in Paraguay, 2023](#)**

Special report | Spanish

19 Dec 2024

**[Experiences and Challenges of the Ecuadorean National Advisory Commission on Serious Events Supposedly Attributable to Vaccination or Immunization, 2020-2023](#)**

Special report | Spanish

19 Dec 2024

**[Rapid vaccination monitoring and its impact on vaccination coverage for high-quality catch-up campaigns in the Dominican Republic, 2023](#)**

Original research | Spanish

19 Dec 2024

**[Risk factors and control measures in measles outbreaks in countries of the Region of the Americas, 2017-2023](#)**

Special report | Spanish

19 Dec 2024

**[High-quality follow-up measles and rubella vaccination campaign in Mexico, 2021](#)**

Special report | Spanish

**Risk Analysis**

Volume 44, Issue 12 Pages: 2755-2934 December 2024

<https://onlinelibrary.wiley.com/toc/15396924/current>

***Special Issue: Risk Science Foundations and COVID EDITORIAL***

**[Special issue: Risk science foundations in light of COVID-19](#)**

Terje Aven, Louis Anthony Cox Jr., Roger Flage, Seth D. Guikema, Charles N. Haas

Pages: 2759-2761 First Published: 11 December 2024

***ORIGINAL ARTICLE***

**[A risk science perspective on vaccines](#)**

Ingrid Glette-Iversen, Terje Aven, Roger Flage

Pages: 2780-2796 First Published: 25 September 2023

**[The foundations of influencing policy and practice: How risk science discourse shaped government action during COVID-19](#)**

Duncan Shaw, Judy Scully

Pages: 2889-2905 First Published: 02 September 2023

**[Multiregional, multi-industry impacts of fairness on pandemic policies](#)**

Leili Soltanisehat, Kash Barker, Andrés D. González

Pages: 2906-2934 First Published: 25 April 2024

**Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 03 Jan 2025]

[No new digest content identified]

## Science

<https://www.science.org/toc/science/current>

**Volume 387/ Issue 6729/ 3 Jan 2025**

*Editorial*

### **Steady going in 2025**

BY H. Holden Thorp, Valda Vinson, Lauren Kmec

02 Jan 2025

As the calendar turns to 2025, the unflagging pace of advancement in science and technology promises to break new ground in areas as profound as humanity's relationship with artificial intelligence (AI), gene editing in medicine and agriculture, climate change mitigation, and more. Meanwhile, as research across all fields becomes more complex, the challenge of maintaining research integrity and the reliability of scientific findings becomes more important than ever for informing public policies and bolstering trust in science. All organizations in the scientific enterprise have a responsibility to ensure that sound practices and ethical standards are at the heart of their operations and missions. This includes scientific journals...

**Volume 386/ Issue 6728/ 20 Dec 2024**

*Feature*

### **Congo's mpox crisis**

BY Jon Cohen

19 Dec 2024: 1336-1343

For the second time in 2 years, a long-overlooked virus poses a global threat. Can it be contained?

*RELATED Letter*

### **Conflict drives mpox epidemic in eastern DRC**

BY Misaki Wayengera

Science 19 Dec 2024

*Policy Forum Biosecurity*

### **Confronting risks of mirror life**

Broad discussion is needed to chart a path forward

Katarzyna P. Adamala, Deepa Agashe, Yasmine Belkaid, Daniela Matias de C. Bittencourt, [...] , and Maria T. Zuber

*Abstract*

All known life is homochiral. DNA and RNA are made from "righthanded" nucleotides, and proteins are made from "left-handed" amino acids. Driven by curiosity and plausible applications, some researchers had begun work toward creating lifeforms composed entirely of mirror-image biological molecules. Such mirror organisms would constitute a radical departure from known life, and their creation warrants careful consideration. The capability to create mirror life is likely at least a decade away and would require large investments and major technical advances; we thus have an opportunity to consider and preempt risks before they are realized. Here, we draw on an indepth analysis of current technical barriers, how they might be eroded by technological progress, and what we deem to be unprecedented and largely overlooked risks ([1](#)). We call for broader discussion among the global research community, policy-makers, research funders, industry, civil society, and the public to chart an appropriate path forward.

## **Science and Engineering Ethics**

Volume 30, Issue 6 December 2024

<https://link.springer.com/journal/11948/volumes-and-issues/30-6>

[Reviewed earlier]

### **Science Translational Medicine**

<https://www.science.org/toc/stm/current>

**Volume 17/ Issue 779/ 1 Jan 2025**

[New issue; No digest content identified]

**Volume 16/ Issue 778/ 18 Dec 2024**

[New issue; No digest content identified]

### **Scientific Reports**

<https://www.nature.com/srep/articles?type=article>

[Accessed 03 Jan 2025]

[No new digest content identified]

### **Social Science & Medicine**

Volume 364 January 2025

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/364/suppl/C>

Research articleOpen access

**["Vaccines protect both you and your newborn:" A discourse analysis of risk and uncertainty in information about vaccination in pregnancy](#)**

Terra Manca

Article 117526

### **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 03 Jan 2025]

[No new digest content identified]

### **Theoretical Medicine and Bioethics**

Volume 45, Issue 6 December 2024

<https://link.springer.com/journal/11017/volumes-and-issues/45-6>

[Reviewed earlier]

### **Travel Medicine and Infectious Diseases**

Volume 62 November–December 2024

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/62/suppl/C>

[Reviewed earlier]

### **Tropical Medicine & International Health**

Volume 29, Issue 12 Pages: i-iv, 991-1062 December 2024

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

### **Vaccine**

Volume 43, Part 1 1 January 2025

<https://www.sciencedirect.com/journal/vaccine/vol/43/part/P1>

*Review article Abstract only*

**[Breakthroughs and insights: A comprehensive review of yellow fever vaccine breakthrough infection across 8 decades](#)**

Felicity J. Coulter, William B. Messer

Article 126423

*Research article Abstract only*

**[Assessment of the BNT162B2 COVID-19 vaccine immune response in Brazilian indigenous adolescents](#)**

Laís Albuquerque de Oliveira, Isa Rita Brito de Moraes, Silvana Beutinger Marchioro, Gabriel Barroso de Almeida, ... Simone Simionatto

Article 126494

*Research article Open access*

**[Pertussis vaccination coverage in women at two months postpartum and associated factors in France, National Perinatal Survey 2021](#)**

Lisa Dilange, Fatima Ait El Belghiti, Virginie Demiguel, Olivia Anselem, ... ENP-2021 Study Group and ENP-DROM 2021 Study Group

Article 126502

*Research article Open access*

**[Improving the timeliness and equity of preschool childhood vaccinations: Mixed methods evaluation of a quality improvement programme in primary care](#)**

Milena Marszalek, Meredith K.D. Hawking, Ana Gutierrez, Nicola Firman, ... Carol Dezateux

Article 126522

## **Vaccines**

<https://www.mdpi.com/journal/vaccines>

[Accessed 03 Jan 2025]

*Open Access Article*

**[The Addis Declaration on Immunization: Assessing the Effectiveness and Efficiency of Immunization Service Delivery Systems in Africa as of the End of 2023](#)**

by Franck Mboussou, Charles Shey Wiysonge, Bridget Farham, Ado Bwaka, Sarah Wanyoike, Amos Petu, Sidy Ndiaye, Andre Bitu Fouda, Johnson Muluh Ticha, Adidja Amani, Regis Obiang, Magaran Monzon Bagayoko and Benido Impouma

Vaccines 2025, 13(1), 13; <https://doi.org/10.3390/vaccines13010013> - 27 Dec 2024

*Abstract*

Background/Objectives: The Addis Declaration on Immunization (ADI) is a historic pledge aiming at increasing political will to achieve universal access to immunization services and includes ten commitments to shape the future of immunization in Africa. Methods: To analyze African countries' performance

*Open Access Review*

**[Boosting Vaccine Research: The 16-Year Journey of TRANSVAC Vaccine Infrastructure](#)**

by William Martin, Catarina Luís, Stefan Jungbluth, Monika Slezak, Frank A. W. Verreck, Holger Spiegel, Carlos A. Guzman, António Roldão, Manuel J. T. Carrondo, Peter Van der Ley, Joaquim Segalés, Hazel M. Dockrell, Mei Mei Ho, Gabriel K. Pedersen, Maria Lawrenz and Ole F. Olesen

Vaccines 2024, 12(12), 1446; <https://doi.org/10.3390/vaccines12121446> - 22 Dec 2024

*Abstract*

TRANSVAC represents a long-running effort to accelerate the development of novel vaccines by integrating institutions from across Europe under a single collaborative framework. This initiative has empowered the global vaccine community since 2009 including contributing toward the development and optimization of vaccine candidates

*Open Access Perspective*

**Platform Technology in Global Vaccine Regulation: Development, Applications, and Regulatory Strategies with Insights from China**

by Xiaojing Li, Su Jin, Shuyang Guo, Dan Yang, Wenbo Sai, Xiao Qiu, Xin Zhao, Lan Wang, Tao Wang and Min Li

Vaccines 2024, 12(12), 1436; <https://doi.org/10.3390/vaccines12121436> - 20 Dec 2024

*Abstract*

The concept of “platform technology” gained prominence after the Ebola outbreak and since then has become essential to international vaccine (prophylactic vaccines against infectious disease) regulatory frameworks. Its significance was further amplified during the COVID-19 pandemic, where platform technology enabled the rapid development [

*Open Access Review*

**Scoping Review of Current Costing Literature on Interventions to Reach Zero-Dose Children in Low- and Middle-Income Countries**

by Ann Levin, Teemar Fisseha, Heidi W. Reynolds, Gustavo Corrêa, Tewodaj Mengistu and Nancy Vollmer

Vaccines 2024, 12(12), 1431; <https://doi.org/10.3390/vaccines12121431> - 19 Dec 2024

*Abstract*

Introduction: A limited number of studies focus on estimating the costs of interventions to increase childhood immunization coverage in low- and middle-income countries (LMICs). Existing reviews often compare estimated costs but lack information on the methods used. The objective of this review is

*Open Access Review*

**Seasonal Influenza Vaccination Programs in the Americas: A Platform for Sustainable Life-Course Immunization and Its Role for Pandemic Preparedness and Response**

by Francisco Nogareda, Margherita Ghiselli, Martha Velandia-González, Bremen de Mucio, Jorge Jara, Paula Couto, Angel Rodriguez, Marc Rondy, Andrea Vicari, Murat Hakan Ozturk, Shoshanna Goldin, Alba Vilajeliu, Eva Leidman, Jaymin Patel, Julie Carlton, Ashley L. Fowlkes, Eduardo Azziz-Baumgartner, Daniel Salas Peraza and Alba Maria Roperio

Vaccines 2024, 12(12), 1415; <https://doi.org/10.3390/vaccines12121415> - 16 Dec 2024

*Abstract*

Background: Vaccination is one of the most effective measures to prevent influenza illness and its complications. Since the 1980s, countries and territories in the Americas have progressively implemented influenza vaccina

**Value in Health**

December 2024 Volume 27 Issue 12 p1635-1804

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

**World Development**

Volume 185 January 2025

<https://www.sciencedirect.com/journal/world-development/vol/184/suppl/C>

[New issue; No digest content identified]

.....  
.....

### ***Contents [click to move among sections]***

:: [\*Milestones, Perspectives\*](#)

:: [\*WHO\*](#)

:: [\*Organization Announcements\*](#)

:: [\*Journal Watch\*](#)

:: [\*Pre-Print Servers\*](#)

.....  
.....

### ***Pre-Print Servers***

#### **arxiv**

<https://arxiv.org/>

[Accessed 03 Jan 2025]

*[Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]*

[arXiv:2412.15319](#)

[Submitted on 19 Dec 2024]

**[Do the unvaccinated disproportionately harm the vaccinated in a respiratory pandemic?](#)**

Denis G. Rancourt, Joseph Hickey

A parameter  $\psi$  was recently defined and introduced into the epidemiological modelling scientific literature, and is being accepted. The said parameter was used to argue that there was a disproportionate risk of infection incurred by vaccinated persons due to contacts with unvaccinated persons during the declared COVID-19 pandemic. Opposing published results show that, in general, there is virtually never a disproportionate risk to the vaccinated from the unvaccinated during a respiratory pandemic. Here, we show that the newly introduced vaccinology parameter  $\psi$  is incorrectly defined and that the conclusions of disproportionate risk are not valid. Specifically, we prove that the originating authors Fisman et al. (2022, 2024) incorrectly defined and applied the parameter  $\psi$ . Their application would imply that the said risk increases with increasing segregation from the unvaccinated (up to complete segregation), increases with increasing vaccination coverage (up to complete coverage) and increases with increasing vaccine efficacy (up to perfect vaccine efficacy), which is impossible. Use of the erroneous parameter  $\psi$  has the potential to encourage unnecessarily aggressive public health policies and interventions.

#### **Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 03 Jan 2025]

[No new digest content identified]

#### **medRxiv**

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 03 Jan 2025]

*[Filter: All articles]*



### **Exploring Drug Repurposing for Rare Diseases: Leveraging Biomedical Knowledge Graphs and Access to Scientific Literature**

Anton Yuryev, Maria Shkrob, Alex Tropsha, Grant Mitchell

medRxiv 2024.12.31.24319817; doi: <https://doi.org/10.1101/2024.12.31.24319817>

### **Towards Monitoring of Global Health Research: An Exploratory Analysis of Transparency and Stakeholder Engagement**

Samruddhi Suresh Yerunkar, Nicole Hildebrand, Daniel Strech

medRxiv 2024.12.30.24319762; doi: <https://doi.org/10.1101/2024.12.30.24319762>

### **The Threat of Science-Related Populism to Global Public Health: Lessons from Iran**

Nima Taefehshok, Brielle Martens, Iman Beheshti, Rene P Zahedi, Marek J Los, Jason Kindrachuk, Saeid Ghavami

medRxiv 2024.12.28.24319727; doi: <https://doi.org/10.1101/2024.12.28.24319727>

#### **Abstract**

This manuscript explores the impact of science-related populism on public health during the COVID-19 pandemic, with a focus on the situation in Iran. Our analysis, utilizing publicly available data from The Economist and the World Health Organization, demonstrates the consequences of delayed vaccination campaigns. Statistical analysis shows a clear correlation between delayed vaccine introduction and increased excess mortality rates. This trend is particularly pronounced in Iran, where political resistance to Western vaccine imports and the promotion of unproven medical technologies exacerbated the health crisis. Additionally, our time-series analysis links significant surges in COVID-19 deaths to national events and government decisions that likely enhanced virus transmission, indicating direct public health repercussions from delayed pandemic responses. These results highlight the global security threat posed by science-related populism, where political agendas undermine scientific integrity and public health. The findings advocate for an urgent global commitment to uphold scientific evidence as the cornerstone of health policy, emphasizing the necessity of combating misinformation to ensure timely and effective public health measures.

### **The association between routine immunisation and COVID-19 vaccination in small island developing states**

Cyra Patel, Gizem Bilgin, Andrew Hayen, Martyn Kirk, Akeem Ali, Aditi Dey, Ginny Sargent, Meru Sheel

medRxiv 2024.12.28.24319741; doi: <https://doi.org/10.1101/2024.12.28.24319741>

### **Influences on rural HPV vaccine hesitancy: A multi-level mixed methods study**

Sherri Sheinfeld Gorin, Arturas Klugas, Matthew Stack, Samantha Chuisano, Hannah Knoll, Cornelius D. Jamison, Angela McGrady, Dongru Chen, Rebecca Hyman, Melissa DeJonckheere

medRxiv 2024.12.29.24319671; doi: <https://doi.org/10.1101/2024.12.29.24319671>

### **COVID-19 Vaccine Safety Studies among Vulnerable Populations: A Systematic Review and Meta-analysis of 120 Observational Studies and Randomized Clinical Trials**

Sima Mohammadi, Malede Mequanent Sisay, Putri Widi Saraswati, Alhadi Khogali Osman, Nicolaas.P.A. Zuithoff, Daniel Weibel, Miriam Sturkenboom, Fariba Ahmadizar

medRxiv 2024.12.27.24319417; doi: <https://doi.org/10.1101/2024.12.27.24319417>

### **Monitoring COVID-19 Occurrence in a Resource-limited Setting – COVID-19 Sentinel Surveillance in Malawi**

Godwin Ulaya, Alinune Kabaghe, Christel Saussier, Ellen MacLachlan, Joshua Smith-Sreen, Chaplain Katumbi, George Bello, Terence Tafatatha, Limbikani Chaponda, Bernard Mvula, Matthews Kagoli, Benson Chilima, Joseph Bitilinyu-Bangoh, Laphiod Chisuwo, Yusuf Babaye, Moses Chitenje, Barbara Bighignoli, Fred Bangara, Ireen Namakhoma, Annie Chauma-Mwale, Gabrielle O'Malley, Kelsey Mirkovic, Nellie Wadonda-Kabondo

medRxiv 2024.12.23.24319583; doi: <https://doi.org/10.1101/2024.12.23.24319583>

### **Over a Century of Infectious Disease Surveillance in Canada: Introducing the Canadian Disease Incidence Dataset (CANDID)**

David J. D. Earn, Gabrielle MacKinnon, Samara Manzin, Michael Roswell, Steve Cygu, Chyunfung Shi, Benjamin M. Bolker, Jonathan Dushoff, Steven C. Walker

medRxiv 2024.12.20.24319425; doi: <https://doi.org/10.1101/2024.12.20.24319425>

### **The impact of introducing meningococcal C/ACWY booster vaccination among adolescents in Germany: a dynamic transmission modelling study**

Felix Günther, Ulrich Reinacher, Sarah Chisholm, Matas Griskaitis, Michael Höhle, Stefan Scholz, Viktoria Schönfeld, Ole Wichmann, Thomas Harder, Frank G. Sandmann

medRxiv 2024.12.19.24319393; doi: <https://doi.org/10.1101/2024.12.19.24319393>

### **Safety Monitoring of Mpox Vaccines in Adults Aged 18-64 Years during the 2022 Mpox Outbreak in the U.S.**

Joann F Gruber, Kathryn Matuska, Carla E Zelaya, Jing Wang, Cheryl N McMahon-Walraven, Lauren Peetluck, Alex Secora, Shwetha Krishnakumar, Mao Hu, Kandace L. Amend, Jennifer Song, Daniel C Beachler, Patricia C Lloyd, Yoganand Chillarige, Jane A Gwira, Wafa Tarazi, Tainya C Clarke, Djeneba Audrey Djibo, Richard Forshee, Azadeh Shoaibi, Steven A Anderson

medRxiv 2024.12.17.24319168; doi: <https://doi.org/10.1101/2024.12.17.24319168>

### **Systematic Review and Meta-Analysis of Retention and Disengagement After Initiation on Antiretroviral Therapy in Low- and Middle-Income Countries After the Introduction of Universal Test and Treat Policies**

Amy Zheng, Emma M. Kileel, Alana T. Brennan, David B. Flynn, Sydney Rosen, Matthew P. Fox

medRxiv 2024.12.18.24319250; doi: <https://doi.org/10.1101/2024.12.18.24319250>

### **Global estimates of lives and life-years saved by COVID-19 vaccination during 2020-2024**

John P.A. Ioannidis, Angelo Maria Pezzullo, Antonio Cristiano, Stefania Boccia

medRxiv 2024.11.03.24316673; doi: <https://doi.org/10.1101/2024.11.03.24316673> Revision

### **Addressing inequalities in vaccination coverage among children aged 12 to 23 months in ten Sub-Saharan African countries: Insights from DHS and MIS Data (2017-2022)**

Sancho Pedro Xavier, Manuel Mahoche, Patrícia Helen Rondó, Ageo Mário da Silva, Renzo Flores-Ortiz, Audêncio Victor

medRxiv 2024.12.13.24318976; doi: <https://doi.org/10.1101/2024.12.13.24318976>

#### *Abstract*

**Introduction** Vaccination is one of the most effective public health interventions for preventing and controlling infectious diseases, particularly in low- and middle-income countries. This study analyzed disparities in vaccination coverage among children aged 12 to 23 months in ten Sub-Saharan African (SSA) countries.

**Methods** A cross-sectional study using data from Demographic and Health Surveys (DHS) and Multiple Indicator Cluster Surveys (MICS) collected between 2017 and 2022 in ten Sub-Saharan African countries. The primary outcome was full vaccination coverage. Logistic regression models were applied to identify factors associated with the outcome.

**Results** Full vaccination coverage rates varied significantly across countries, with Gambia presenting the highest rate (86.4%) and Guinea the lowest (21.2%). Factors associated with full vaccination coverage included place of residence, maternal education and age, economic status, place of delivery, possession of a health card, and attendance at prenatal care services.

**Conclusion** The study highlighted significant disparities in vaccination coverage among children in Sub-Saharan Africa, influenced by sociodemographic and economic factors. Investing in maternal education,

improving economic conditions, and strengthening healthcare infrastructure are essential measures to reduce these inequalities.

### **OSF Pre-prints**

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

*[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]*

*Selected Research*

*Pre-Print*

#### **The Federated European Genome-phenome Archive as a global network for sharing human genomics data**

Mallory Freeberg, et al.

*Abstract*

In the era of rapidly expanding human genomics in research and healthcare, efficient data reuse is essential to maximise benefits for society. In response, Federated EGA was launched in 2022, and as of 2024, the FEAGA Network is composed of seven national nodes. Here we describe the complexities, challenges, and achievements of FEAGA, unravelling the dynamic interplay between regulatory frameworks, technical challenges, and the shared vision of advancing genomic research.

### **Wellcome Open Research**

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 03 Jan 2025]

*Study Protocol Open Access*

#### **Booster Vaccination against Yellow Fever in Gambian children-(BoVY) -a Phase 3 clinical trial to establish safety and immunogenicity of repeated YF vaccination in healthy Gambian children of different ages**

[version 1; peer review: awaiting peer review]

Beate Kampmann, ET AL.

*Abstract*

*Background*

Yellow fever (YF) is a mosquito-borne and recently re-emerging viral haemorrhagic fever endemic to sub-Saharan Africa and South America. A highly effective vaccine against YF is licensed and recommended as part of routine childhood immunisation as a single dose at 9 months. Recent observational data demonstrate waning immunity following single primary vaccination and suggest that children in endemic areas may require booster vaccination.

\* \* \* \*

### **Think Tanks**

**Brookings** [to 03 Jan 2025]

<http://www.brookings.edu/>

*Research*

#### **Scaling up prenatal and infant cash prescriptions to eradicate deep infant poverty in the United States**

*Sustainable Development Goals*

Mona Hanna, H. Luke Shaefer, Holly Fogle, Joneigh S. Khaldun, Wendy McWeeny, Orriel Richardson, TaShon Thomas, Anthony F. Pipa

December 20, 2024

**Center for Global Development** [to 03 Jan 2025]

<https://www.cgdev.org/>

*All Research*

*POLICY PAPERS*

**Avoiding Another Lost Decade on Malaria Vaccines**

Ryan Duncombe et al.

December 16, 2024

*Abstract*

After decades of research and development, two new malaria vaccines entered routine administration this year, and are projected to save 180,000 children's lives by 2030. But under current plans, roughly 2.5 million children will die of malaria unvaccinated over the same period. What's stopping a faster rollout? Money is the obvious answer. Nigeria, home to a third of global malaria deaths, has a total health budget of \$10 per capita, and qualifies for only limited international assistance to purchase a vaccine that costs more than \$15 per child for even the generic R21 variety. Poorer countries like the Democratic Republic of Congo have received highly subsidized vaccines, but will struggle to ensure take-up for a four-dose regimen without additional expenditure on community outreach and cold-chain management. Despite these financing challenges, malaria vaccines appear highly cost effective, at around \$4,200 per life saved, rivaling some of the best buys in global health. While policymakers must weigh malaria spending against other disease priorities, the advent of vaccines implies malaria can absorb more resources while maintaining higher cost effectiveness than ever before. The most ambitious rollout would exceed the malaria budget of Gavi, the Vaccine Alliance, by \$2 to \$3 billion over the next five years.

**Chatham House** [to 03 Jan 2025]

<https://www.chathamhouse.org/>

*Selected Analysis, Comment, Events*

*No new digest content identified.*

**Council on Foreign Relations** [to 03 Jan 2025]

<https://www.cfr.org/media/news-releases>

*New Releases [Selected]*

*No new digest content identified.*

**CSIS** [to 03 Jan 2025]

<https://www.csis.org/>

*Reports [Selected]*

**The United States Needs to Step Up Its Response to Bird Flu**

The United States continues to fall short in managing the threat of bird flu. Although the risk of widespread H5N1 human-to-human transmission currently appears low, enhanced response measures are needed to protect the health and national security of the United States.

Digital Report by Michaela Simoneau, Sophia Hirshfield, and Maclane Speer — December 19, 2024

**Kaiser Family Foundation** [to 03 Jan 2025]

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

*Newsroom*

*No new digest content identified.*

**McKinsey Global Institute** [to 03 Jan 2025]

<https://www.mckinsey.com/mgi/overview>

*Latest Research*

**McKinsey Global Institute: 2024 in charts**

December 12, 2024 -

Here are some of the McKinsey Global Institute’s favorite data visualizations from 2024.

**ODI [Overseas Development Institute]** [to 03 Jan 2025]

<https://odi.org/en/publications/>

*Publications [Selected]*

*No new digest content identified.*

**Pew Research Center** [to 03 Jan 2025]

<https://www.pewresearch.org/>

*Latest Publications [Selected]*

*No new digest content identified.*

**Rand** [to 03 Jan 2025]

<https://www.rand.org/pubs.html>

*Published Research [Selected]*

*No new digest content identified.*

**Urban Institute** [to 03 Jan 2025]

<https://www.urban.org/publications>

**New Research Publications - Selected**

**World Economic Forum** [to 03 Jan 2025]

<https://agenda.weforum.org/press/>

*Media [Selected]*

*No new digest content identified.*

*	*	*	*
*	*	*	*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy ([CVEP](#)) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

*Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.*

*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*